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Abstract 
Background  
The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing 
Guidelines on Allergen Immunotherapy (AIT) for Allergic Rhinoconjunctivitis. In order to inform the 
development of clinical recommendations, we undertook a systematic review to assess the effectiveness, 
cost-effectiveness and safety of AIT in the management of allergic rhinoconjunctivitis 
 
Methods  
We searched 15 international biomedical databases for published, in progress and unpublished evidence.  
Studies were independently screened by two reviewers against pre-defined eligibility criteria and critically 
appraised using established instruments.  Our primary outcomes of interest were symptom, medication 
and combined symptom and medication scores. Secondary outcomes of interest included cost-
effectiveness and safety. Data were descriptively summarized and then quantitatively synthesized using 
random-effects meta-analyses.   
 
Results 
We identified 5932 studies of which 160 studies satisfied our eligibility criteria. There was a substantial 
body of evidence demonstrating significant reductions in standardized mean differences (SMD) of 
symptom (SMD -0.53, 95%CI -0.63, -0.42), medication (SMD -0.37, 95%CI -0.49, -0.26) and combined 
symptom and medication (SMD -0.49, 95%CI -0.69, -0.30) scores whilst on treatment that were robust to 
pre-specified sensitivity analyses.   There was in comparison a more modest body of evidence on 
effectiveness post-discontinuation of AIT, this suggesting a benefit in relation to symptom scores.  
 
Conclusions 
AIT is effective in improving symptom, medication and combined symptom and medication scores in 
patients with allergic rhinoconjunctivitis whilst on treatment, and there is some evidence suggesting that 
these benefits are maintained in relation to symptom scores after discontinuation of therapy.  
  
Keywords: Allergen, allergy, allergic rhinoconjuctivitis, desensitization, allergen immunotherapy, rhinitis, 
subcutaneous, sublingual 
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BACKGROUND  
Allergic rhinoconjunctivitis is a very common chronic condition that can result in considerable morbidity 
and impairment of quality of life.(1,2) The disease is triggered by exposure to seasonal and/or perennial 
allergens and, depending on the nature of the allergenic trigger(s) and patterns of exposure, symptoms 
may be persistent or intermittent.(3) Allergic rhinitis is typically characterized by symptoms of nasal 
obstruction, a watery nasal discharge, sneezing and itching, and there is often (but not invariably) 
involvement of the conjunctiva (allergic conjunctivitis), which manifests with itching, injection and 
tearing.(4) There may in addition be an impact on the ability to concentrate, on school and work 
performance,(5,6) and interference with daily activities and sleep; furthermore, allergic rhinitis is a risk 
factor for the development of asthma.(7) 
 
Symptoms can, in many cases, be controlled with avoidance measures and pharmacological therapies such 
as oral, intranasal and topical (ophthalmic) H1-antihistamines, intranasal corticosteroids and anti-
leukotrienes, as mono-therapy or in combination.(8,9) Allergen immunotherapy (AIT) is an additional 
potential treatment option, particularly for those with more troublesome disease which remains 
inadequately controlled despite avoidance measures and regular  pharmacotherapy.(8–10) The problem of 
inadequately controlled  allergic rhinoconjunctivitis, despite optimal medical treatment, continues to 
represent a therapeutic challenge in the majority of patients. 
 
The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing 
Guidelines on AIT for Allergic Rhinoconjunctivitis and this systematic review has been undertaken in 
order to inform the formulation of key clinical recommendations. Specifically, we sought to assess the 
effectiveness, cost-effectiveness and safety of AIT in patients with allergic rhinoconjunctivitis.(11) 
 
 
METHODS  
As our methods have been reported in detail in our published protocol,(12) we confine ourselves to a 
synopsis of the methods employed.  
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Search strategy 
A highly sensitive search strategy was developed and validated study design filters were applied to search 
15 electronic bibliographic databases. The search strategy was developed on OVID MEDLINE and then 
adapted for the other databases (see Appendix 1, supplementary file for details). In all cases, the databases 
were searched from inception to October 31, 2015.  Additional references were located through searching 
the references cited by the identified studies, and unpublished work, while research in progress was 
identified through discussion with experts in the field. We invited experts from a range of disciplines and 
regions to add to the list of included studies by identifying additional published and unpublished papers 
they were aware of and research in progress. There were no language restrictions employed; where 
possible, relevant literature was translated into English.  
 
Inclusion criteria 
We focused on studies conducted on patients of any age with allergic rhinoconjunctivitis investigating the 
effect of AIT. See Box 1 for full details.  
 
Patient 
characteristics 
 
Studies conducted on patients of any age with a physician-confirmed diagnosis of allergic 
rhinoconjunctivitis or allergic rhinitis, plus evidence of clinically relevant allergic sensitization 
(e.g., skin prick test or specific-IgE). 
Interventions 
of interest  
 
AIT for different allergens (e.g. pollen, house dust mites (HDM), animal dander, cockroach and 
molds), including modified allergens, administered through the subcutaneous (SCIT), sublingual 
(SLIT), intralympahtic (ILIT) or any other routes. 
Comparator Placebo or any active comparator. 
Study designs  
 
Effectiveness: Robust double-blind RCTs. Originally, we planned to include data from any RCT, 
irrespective of whether there was blinding.  This was changed due to the volume of RCT studies. 
This decision was made prior to any analyses being undertaken.  
Cost-effectiveness: health economic analysis.  
Safety: double-blind RCTs and large case series (≥300 patients). 
Study 
outcomes 
Primary outcomes: effectiveness, both short-term (i.e. during treatment) and long-term (i.e. at least a 
year after discontinuation of AIT)  as assessed by symptom and/or medication scores.   
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 Secondary outcomes: disease specific quality of life (QoL); threshold of allergen exposure to trigger 
symptoms on allergen challenge or in an environmental exposure chamber; health economic 
analysis from the perspective of the health system/payer; and safety as assessed by local and 
systemic reactions in accordance with the World Allergy Organization’s (WAO) grading system 
of side-effects.(14,15)  
Exclusion 
criteria 
Reviews, discussion papers, non-research letters and editorials, animal studies and studies not 
employing double-blind RCT designs. 
 
Box 1. Inclusion and exclusion criteria 
Study selection 
All references were uploaded into the systematic review software DistillerSR and underwent initial de-
duplication.  Study titles were independently checked by two reviewers (SD and UN) according to the 
above selection criteria and categorized as included, not included or unsure. For those papers in the 
unsure category, we retrieved the abstract and re-categorized as above. Any discrepancies were resolved 
through discussion and, if necessary, a third reviewer (AS) was consulted. Full text copies of potentially 
relevant studies were obtained and their eligibility for inclusion independently assessed by two reviewers 
(SD and UN). Studies that did not fulfil all of the inclusion criteria were excluded.  
 
Quality assessment strategy 
Quality assessments were independently carried out on each study by two reviewers (UN, SA, AA, MA or 
TM) using a range of instruments. RCTs were assessed for generation of allocation sequence, 
concealment of allocation, baseline outcome measurements, baseline characteristics, incomplete outcome 
data, blinding of outcome assessor, protection against contamination, selective outcome reporting and 
other risks of bias using the Cochrane Risk of Bias (ROB) Tool.(13)  We used the Critical Appraisal Skills 
Programme (CASP) Economic Evaluation Checklist for health economic studies.(14) For case series, we 
used the quality assessment tool produced by the National Institute for Health and Clinical Excellence 
(NICE).(15) Any disagreements were resolved through discussion and, if necessary, a third reviewer (SD 
or AS) was consulted. 
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Data extraction, analysis and synthesis 
Data were independently extracted onto a customized data extraction sheet in DistillerSR by two 
reviewers (UN, SA, AA, MA, SD or TM), and any discrepancies were resolved by discussion or, if 
agreement could not be reached, by arbitration by a third reviewer (SD or AS). A descriptive summary 
with detailed data tables was initially produced to summarize the literature.  Where clinically and 
statistically appropriate, meta-analyses were undertaken using random-effects modeling.(16) Data were 
extracted from primary studies, but where these were not available in a suitable format we first contacted 
authors for data and then if data were still not available we extracted data from previous Cochrane 
reviews.   For outcomes for which it was not possible to produce a meta-analysis, we narratively 
synthesized data. Heterogeinity statistics are reported with each forest plot.  
 
Sensitivity analyses and assessment for publication bias 
Sensitivity analyses were undertaken for the primary outcomes by comparing the summary estimates 
obtained by excluding studies considered to be at high ROB.   
Publication bias was assessed for these same primary outcomes through the creation of funnel plots, and 
tested by Egger's regression test and Begg's rank correlation test.(17,18) 
 
Subgroup analyses 
A number of subgroup analyses were undertaken, which are listed in the protocol.  
 
Registration and reporting 
This review is registered with the International Prospective Register of Systematic Reviews 
(PROSPERO): http://www.crd.york.ac.uk/prospero/.  The registration number is CRD42016035373. 
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist has been 
used to guide the reporting of this systematic review: http://www.prisma-statement.org/ (Appendix 2, 
Supplementary file). 
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RESULTS  
Our search strategy yielded 5,932 titles of which 161 studies (reported in 166 papers) met our overall 
review eligibility criteria.  These eligible papers included 135 double-blind RCTs, 19 health economic 
analyses and seven case series (Figure 1).  
 
Effectiveness  
Description of trials  
We identified 61 SCIT RCTs (reported in 63 papers) (19–81) including 6,379 patients, 71 SLIT RCTs 
(reported in 75 papers) (82–119,119–121,121–156) including 13,636 patients and two ILIT RCTs 
(157,158) including 56 patients (Tables 1a-c).  The majority of studies only included adult participants. A 
range of allergens were assessed including weed, tree and grass pollens, moulds, cat and dog dander and 
house dust mites. A range of AIT protocols were utilized. The overwhelming majority of trials only 
reported on short-term effectiveness (Tables S2a-c). A full description of the trials is given in the online 
supplement.  
 
Quality assessment  
SCIT 
Overall, the quality of included studies was high. Thirty-seven studies were found to be at low ROB, eight 
studies at high ROB, and 16 were judged at unclear ROB (Table S2d). 
 
SLIT 
The quality of studies was assessed to be low ROB in 26 studies, high ROB in 16 studies and unclear 
ROB in 28 studies (Table S2e). In one study, ROB could not reliably be assessed from the translation. 
 
ILIT 
Both studies had a low ROB (Table S2f).  
 
Primary outcomes 
Data on primary outcomes are summarized in Tables S2 g-i .   
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Symptom scores 
Short-term   
105 studies reported on the short-term effectiveness of AIT administered by the SCIT (n=51), SLIT 
(n=52) and ILIT (n=2) routes assessed by symptom scores.   
 
We were able to pool data from 58 SCIT and SLIT studies assessing the effectiveness of AIT by 
symptom scores. This showed a standardized mean difference (SMD) of -0.53 (95%CI -0.63, -0.42) this 
suggesting a moderate effect in favor of AIT (Figure 2).  
 
Sensitivity analysis 
Sensitivity analysis was performed excluding all studies at high ROB, which demonstrated a SMD of -0.57 
(95%CI -0.68,-0.46) (Figure S1, Supplementary file) 
 
Assessment for publication bias 
There was evidence of potential publication bias (Figure S2, Supplementary file) which was also suggested 
by the Begg (P=0.003) and Egger (P=0.003) tests. 
 
Subgroup analyses 
Subgroup analyses were undertaken to compare: 
 SCIT versus SLIT: SMD -0.65 (95%CI -0.86, -0.43) for SCIT and SMD -0.48 (95%CI -0.61, -
0.36) for SLIT (Figures 3a and b), these both showing evidence of benefit; data from the two 
ILIT trials could not be pooled, but these studies also demonstrated an improvement in short-
term symptom scores. 
 Children versus adults for AIT (SCIT and SLIT): SMD -0.25 (95%CI -0.46, -0.05) for children 
and SMD -0.56 (95%CI -0.70, -0.42) for adults (Figures 4a and b), these analyses showing 
evidence of benefit in both adults and  children. 
 Children versus adults for SLIT only: SMD -0.42 (95%CI -0.63, -0.21) for children and SMD -
0.47 (95%CI -0.64, -0.29) for adults (figures S3a and b), these analyses showing benefit in both 
adults and children.  
 Seasonal versus perennial allergens: SMD -0.37 (95%CI -0.45, -0.28) for seasonal and SMD -0.91 
(95%CI -1.47, -0.36) for perennial (Figures S4a and b, Supplementary file), these demonstrating 
evidence of benefit from both approaches. 
 Seasonal versus perennial allergens for SCIT: SMD -0.49 (95%CI -0.72, -0.27) for seasonal and 
SMD -1.59 (95% CI -2.44, -0.74)for perennial (results from only one study) (Figures S5a and b, 
Supplementary file), these demonstrating evidence of benefit from both approaches. 
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 Seasonal versus perennial allergens for SLIT: SMD -0.35 (95%CI -0.45, -0.26) for seasonal and 
SMD         -0.81 (95%CI -1.41, -0.20)for perennial allergens  (Figures S6a and b, Supplementary 
file)  
 Pre-/co-seasonal versus continuous treatment in SCIT for pollen: SMD -0.51 (95%CI -0.63, -
0.38) in pre/co-seasonal and  SMD -0.69 (95%CI -1.09, -0.29) (Figures S7a and b, 
Supplementary file), these analyses demonstrating evidence of benefit from both approaches. 
 Pre-/co-seasonal versus continuous treatment in SLIT for pollens : SMD -0.40 (95%CI -0.48, -
0.32) in pre-/co-seasonal and SMD -0.55 (95%CI -0.98, -0.11) in continuous (Figures S8a and b, 
Supplementary file), these analyses demonstrating a clear benefit associated with both 
approaches. 
 Modified allergen extracts (allergoids) versus unmodified allergen extracts in SCIT: SMD -0.60 
(95%CI    -0.89, -0.31) versus SMD -0.65 (95%CI -0.93, -0.36) (Figures S9a and b, 
Supplementary file), these analyses demonstrating evidence of benefit from both modalities 
 Aqueous solutions versus tablets in SLIT: SMD -0.41 (95%CI -0.65, -0.18) in aqueous and SMD 
-0.56 (95% CI -0.80, -0.33) with tablets (Figures S10a and b, Supplementary file), these analyses 
confirming benefit with both preparations.  
 Different allergens for AIT (SCIT and SLIT): HDM: SMD -0.73 (95%CI -1.37, -0.10); grass: 
SMD               -0.45 (95%CI -0.54,-0.36); tree: SMD -0.57 (95%CI -0.92, -0.21); molds: SMD -
0.56 (95%CI -2.29, 1.18); weeds: SMD -0.68 (95%CI -1.06, -0.30), these showing that AIT was 
clearly effective for all allergens except molds for which there was evidence suggestive of benefit 
but this was imprecisely estimated  (Figures S11a, b, c, d and e, Supplementary file), 
Long-term 
In order to investigate long-term effectiveness, a number of investigators studied a discontinuation period 
following trials that involved randomization to AIT or placebo in which the superiority of AIT was 
confirmed.  In this longer-term phase, patients were followed-up and outcomes were then again assessed 
at least one year post-discontinuation of AIT.  
 
There were four trials that studied this outcome, one SCIT (42) and three SLIT (89,114,133), all of which 
were judged to be at low ROB.  Meta-analysis of data was not possible.  A full descriptive summary of the 
main findings are provided in the supplement. In summary, all four trials at low ROB found a beneficial 
effect on the long-term effectiveness of AIT on symptom scores.  
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Medication scores 
Short-term  
89 studies reported on the short-term effectiveness of AIT administered by the SCIT (n=46), SLIT 
(n=42) and ILIT (n=1) routes on medication scores.  
 
We were able to pool data from 45 SCIT and SLIT trials. This showed an overall SMD of -0.38 (95%CI -
0.49,         -0.26), this suggesting a small-to-medium effect in favor of AIT in improving medication 
scores (Figure 5). 
 
Sensitivity analyses 
Sensitivity analysis, performed by excluding all studies at high ROB, gave an SMD of -0.35 (95%CI -0.46, 
-0.24) (Figure S12, Supplementary file). 
 
Assessment of publication bias 
The Funnel plot revealed evidence of potential publication bias (Figure S13, Supplementary file) which 
was also suggested by the Begg (P=0.004) and Egger (P=0.03) tests. 
 
Subgroup analyses 
Subgroup analyses were undertaken to compare: 
 SCIT versus SLIT:  SMD -0.52 (95%CI -0.75, -0.29) for SCIT and -0.31 (95%CI -0.44, -0.18) for 
SLIT (Figures 6a and b), these analyses demonstrating that both routes were effective. 
 Children versus adults: SMD -0.21 (95%CI -0.42, 0.01) for children and SMD -0.43 (95%CI -
0.56, -0.30) for adults (Figure S14a and b, Supplementary file), these showing a clear benefit in 
adults and the suggestion of benefit in children (but this was not confirmed) 
 Children versus adults for SLIT only: SMD -0.60 (95%CI -1.12, -0.07) for children and SMD -
0.45 (95%CI -0.69, -0.22) for adults showing a benefit in both. (Figure S15a and b, 
Supplementary file) 
 Seasonal versus perennial allergens for AIT (SCIT and SLIT): SMD -0.30 (95%CI -0.43, -0.16) 
for seasonal and SMD -0.63 (95%CI -1.12, -0.15) for perennial allergens (Figure S16a and b, 
Supplementary file), these indicating that both were effective. 
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 Seasonal versus perennial allergens for SCIT: SMD -0.77 (95% CI-1.28, -0.25) for seasonal and 
SMD            -0.27 (95%CI -1.01, 0.48) for perennial (results from only one study) (Figure S17a 
and b, Supplementary file)  
 Seasonal versus perennial allergens for SLIT: SMD -0.24 (95% CI -0.38, -0.10) for seasonal, 
SMD -0.72 (95% CI -1.30, -0.13) (Figure S18a and b, Supplementary file), indicating that both 
were effective.  
 Pre/co-seasonal versus continuous treatment in SCIT for pollens: SMD -0.40 (95%CI -0.56, -
0.25) in pre-seasonal and SMD -1.23 (95%CI -2.34, -0.12) in continuous (Figure S19a and b, 
Supplementary file), these indicating that both were effective. 
 Pre-/co-seasonal versus continuous treatment in SLIT for pollens: SMD -0.30 (95%CI -0.42, -
0.18) in pre-/co-seasonal and SMD 0.00 (95%CI -0.32, 0.33) for continuous (Figure S20a and b, 
Supplementary file), these analyses suggesting that pre-/co-seasonal was effective and that 
continuous treatment was ineffective. 
 Modified allergen extracts (allergoids) versus unmodified allergen extracts in SCIT SMD -0.94 
(95%CI     -1.73, -0.16) versus SMD -0.44 (95%CI: -0.64, -0.24) (Figure S21a and b, 
Supplementary file), 
 Aqueous solutions versus tablets in SLIT: SMD -0.35 (95%CI -0.55, -0.14) for those receiving 
aqueous and SMD -0.42 (95%CI -0.64, -0.19) for tablets (Figure S22a and b, Supplementary file), 
these analyses showing that both preparations were effective. 
 Different allergens for AIT (SCIT and SLIT): HDM: SMD-0.63 (95%CI -1.12, -0.15) ) vs Grass: 
SMD-0.32  (95%CI -0.46, -0.18) vs Tree: SMD -0.40 (95%CI -0.59, -0.20) vs Molds: SMD 0.34 
(95%CI -0.41, 1.09)(results from only one study) vs Weeds: SMD -0.44 (95%CI -0.80, -0.09) 
(Figures S23a, b, c, d and e, Supplementary file), these showing evidence of benefit for all 
allergens except molds. 
 
Long-term  
There were three low ROB trials that assessed this outcome: one SCIT (42) and two SLIT. (114,133) 
These three trials are described in detail in the supplement. Overall, one trial found a benefit of AIT 
(SCIT) on long-term medication scores; the two other SLIT trials did not show a sustained effect.   
 
Combined symptom and medication scores 
Twenty-nine studies reported on the short-term effectiveness of AIT administered by the SCIT (n=20) 
and SLIT (n=9) routes on combined symptom and medication scores.  Two studies (one SCIT and one 
SLIT) reported on long-term effectiveness in relation to this outcome.  
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Short-term  
We were able to pool data from 15 studies.  Meta-analysis found a SMD of -0.49 (95%CI -0.69, -0.30), 
this suggesting a small-to-moderate effect in favor of AIT (Figure 7). 
 
Sensitivity analysis 
No sensitivity analysis was possible as no studies were judged to be at high ROB. 
 
Publication bias 
The funnel plot showed evidence of potential publication bias, (Figure S24, Supplementary file) which 
was also suggested by the Begg (P=0.005) and Egger (P=0.03) tests. 
 
Subgroup analyses 
Subgroup analyses were undertaken to compare: 
 SCIT versus SLIT: SMD -0.51 (95%CI -0.77, -0.26) for SCIT and SMD -0.47 (95%CI -0.81, -
0.12) (Figures 8a and b), these analyses showing a benefit from both SCIT and SLIT. 
 Children (<18) versus  adults (≥18 years) for AIT (SCIT and SLIT): SMD -0.85 (95% CI -1.52, -
0.17) (results from one study only) for children and SMD -0.44 (95%CI -0.65, -0.22) for adults 
(Figures S25a and b, Supplementary file), these analyses showing a benefit in both children and 
adults 
 Pre/co-seasonal (short term treatment) versus continuous treatment in SCIT for pollen: SMD -
0.41 (95%CI -0.58, -0.24) for pre-seasonal and SMD -0.86 (95%CI -1.49, -0.22) for continuous 
(results from one study only) (Figures S26a and b, Supplementary file), these analyses showing a 
clear benefit from pre/co-seasonal treatment and the suggestion (but not confirming) benefit 
from continuous treatment 
 Modified allergen extracts (allergoids) versus unmodified allergen extracts in SCIT: SMD -0.49 
(95%CI   -0.79, -0.19) for allergoids and SMD -0.36 (95%CI -0.73, 0.03) (Figures S27a and b, 
Supplementary file), these finding a clear benefit from allergoids and suggesting (but not 
confirming) a benefit from unmodified preparations. 
 Different allergens for AIT (SCIT and SLIT): Grass: SMD -0.41  (95%CI -0.58, -0.24) vs Tree 
(one study only): SMD -0.26 (95%CI -0.64, 0.13) vs Molds: SMD -0.65 (95%CI -2.06, 0.76 ) vs 
Weeds: SMD -0.69 (95%CI -1.24, -0.13) (Figures S28a, b, c and d Supplementary file), this 
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showing clear evidence of benefit for grass and tree pollens, and suggesting (but not confirming) 
evidence of benefit for molds and weeds.. 
 
Long-term  
We found one SCIT trial (53) and two SLIT trials (109,133)that reported on this outcome. These are 
described in detail in the supplement. Overall, one of the three trials found evidence of a sustained 
beneficial effect on combined symptom and medication scores. The one trial at an unclear ROB (Didier 
2013/2015) demonstrated a two year carry over effect of AIT in the active SLIT group that received AIT 
four months pre-seasonally for three consecutive seasons but not for the group which received AIT two 
months pre-seasonally.(109,159) 
 
Secondary outcomes 
Disease-specific quality of life 
Thirty studies reported data on quality of life (QoL): these comprised of SCIT (n=17) (19,20,23,28,33, 
34,35,45,46,55,58,68–70,72,74,79) and SLIT (n=13) (90,99,104,106,108,110,117,129,130,132,140,145,149) 
trials (Tables S2j and k). The majority of trials (n=29) used one of the disease-specific, validated Rhinitis 
Quality of Life Questionnaire (RQLQ) instruments. However, one SLIT study (eligible because it 
reported on other outcomes) used a generic, non-disease specific tool, the SF-36, and this was therefore 
not considered further.(140) Due to inconsistencies of reporting data, it was not possible to pool results 
from all of the studies and no SLIT studies were suitable for inclusion in meta-analysis. Pooling data from 
the six SCIT studies with suitably reported data derived from the original and standardized RQLQ 
instruments found a SMD of -0.35 (95%CI -0.74, 0.04), this corresponding to a likely small-to-medium 
improvement in the AIT group when compared to placebo (Figure 9).    
 
Allergen challenge models in AIT 
A detailed description of environmental exposure chamber, nasal and conjunctival challenge studies are 
described in the supplement. One SCIT  and three SLIT (83,120,121) chamber studies demonstrated the 
effectiveness of AIT. Results of nasal challenge studies for 15 SCIT (23,24,27,29,30,33,37,43,52,57–
59,63,64,75) and 11 SLIT (84,86,87,92,93,122,128,136,139,146,150) (Table S2l) were conflicting making it 
difficult to make clear conclusions. There was no clear evidence of effectiveness in 12 SCIT  
(21,23,35,38,42,45,55,62-64,70,72) and four SLIT conjunctival challenges studies (120,127,138,146) (Table 
S2m). 
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Cost-effectiveness 
Characteristics of studies   
We identified 19 eligible studies that reported on health economic evaluations of SCIT and SLIT in both 
children and adults (Table S2n).(160–178) Studies were based in a range of countries. Seven of the studies 
reported results against disease specific outcome measures whilst the remaining 12 reported results based 
on quality adjusted life years (QALYs). Thirteen of the studies were based on RCT data or meta-analyses 
of RCT data(160–169,176–178).  Full details are in the supplement.  
 
Quality appraisal 
The quality appraisal of the included studies is detailed in Table S2o. 
 
Main findings 
In general, the studies found that AIT, and where defined both SLIT and SCIT, were more effective than 
standard care including pharmacotherapy, but also more expensive. The studies that compared SLIT with 
SCIT gave very mixed results not allowing a clear conclusion to be drawn that either treatment was 
necessarily more effective or more costly than the other from a health system perspective. The studies 
comparing Grazax (SLIT) and Oralair (SLIT) suggested that Oralair is both more effective and cheaper 
than Grazax.(165,167) 
 
For those studies based on RCT data conducted from a health system perspective and using QALYs as 
their outcome measure (n=7), we found that: 
 Nasser 2008: In patients with both rhinitis and asthma in England the incremental cost-
effectiveness ratio (ICER) for SLIT versus standard care was £8816 (€10851) per QALY at 2005 
prices inflated using national health service (NHS) inflation indices (i.e. Personal Social Services 
Research Unit (PSSRU)) to £10726 (€13202)  per QALY at 2014/15 prices. (177) 
 Poulsen 2008: In adult patients with rhino-conjunctivitis in Denmark the ICER for SLIT versus 
standard care was 134105 DKK per QALY (no price year was given so we assumed study year of 
2008) updating to current prices and £ at 0.1 £ per DKK gave an ICER of £15294 (€18824) per 
QALY at 2014/15 prices.(164) 
 Keiding 2007: In adult patients with rhino-conjunctivitis in Austria, Denmark, Finland, Germany, 
Netherlands, Sweden the ICERs of SCIT compared to standard care in 2005 Euro per QALY 
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were 9716, 2586, 13683, 10300, 24519 and 22675, respectively. Updating to current prices and £ 
at 0.75 GBP per Euro gives ICERs of £8866, £2360, £12486, £9399, £22374 and £20691 per 
QALY respectively at 2014/15 prices.(162) 
 Ronaldson 2014: In 5-16 year olds with rhino-conjunctivitis with or without asthma in the UK 
the ICER for SLIT versus standard care was £12168 (€14976) per QALY at 2008 prices. 
Updating to current prices gives an ICER of £13357 (€16440) per QALY at 2014/15 prices.(166) 
 Westerhout 2012: In patients with rhino-conjunctivitis without asthma in Germany the ICER for 
SLIT (Oralair) versus standard care was 14728 euros per QALY at 2011 prices. Converting to 
current prices and GBP at 0.75 £ per Euro gives an ICER of £11460 per QALY.(167) 
 Verheggen 2015: In patients with rhinoconjunctivitis without asthma in Germany the ICER for 
SLIT (Oralair) versus SCIT is 12593 euros per QALY at 2013 prices. Converting to 2014/15 
prices and GBP at 0.75 GBP per Euro gives an ICER of £9627 per QALY(168) 
 Reinhold 2016: In patients with rhinoconjunctivitis without asthma in Germany SCIT 
(Allergovit) is cheaper and more effective than SLIT (Oralair). The ICER for SCIT (Allergovit) 
standard care is 11000 euros per QALY at 2013 prices. Converting to 2014/15 prices and GBP 
at 0.75 GBP per Euro gives an ICER of £8334 per QALY.(169) 
When assessing these results, it was unclear how comparable the patient populations were between the 
studies; a key factor that impacts the costs and quality of life observed is the proportion of patients who 
have asthma as well as rhinitis – these proportions were not reported in the studies. Also noteworthy was 
that the ICERs for AIT seemed to vary substantially between different health systems as demonstrated in 
Keiding et al 2007 where ICERs range from £2360 per QALY in Denmark to £22374 per QALY in the 
Netherlands suggesting that straightforward conclusions may not be generalizable even across seemingly 
similar countries.(162) 
 
Overall interpretation  
The seven key studies identified, disregarding the caveats about generalizability, suggested that SLIT and 
SCIT treatment would be considered cost-effective in this patient population in England at the standard 
NICE cost-effectiveness threshold of £20,000 (€24616) per QALY. However, the quality of the studies 
and the general lack of attention to characterizing uncertainty and handling missing data need to be taken 
into account when interpreting these results.(162,164,166–169,177) 
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Safety 
RCTs and case-series were eligible for inclusion to consider the safety of AIT.  
 
Randomized controlled trials 
Safety data for SCIT and SLIT RCTs are summarised in Tables S2p-v. There was a great variation in 
reporting of adverse events and a number of grading scales including WAO and EAACI were used. As 
detailed in the tables some studies reported limited or unclear data on number of AEs, some studies 
reported no data on AEs and others reported that no AEs occurred at all through the duration of the trial 
period. Conversely some studies reported all treatment emergent AEs.  
Total adverse events 
We were able to pool data for this outcome for total number of adverse events. Safety data for 51 SCIT 
and SLIT RCTs were pooled to give an overall risk ratio (RR) of experiencing an adverse event (AE) of 
1.64 (95%CI:1.43, 1.89).(Figure S3a) 
 
For SCIT studies (n=19), we found an RR of 1.58 (95%CI:1.13, 2.20) of experiencing an AE and for 
SLIT studies (n=32) an RR of 1.68 (95%CI:1.44, 1.98).(Figures S3b and c)  suggesting a comparable 
safety profile for both modes of AIT. 
 
Systemic adverse events 
We were able to pool data for number of systemic AEs for 39 SCIT and SLIT RCTs to give an overall 
RR of experiencing a systemic AE of 1.26 (95%CI:1.03, 1.55).(Figure S3d) For SCIT studies (n=15), we 
found a RR of 1.15 (95%CI: 0.67, 2.00) of experiencing a systemic  AE and for SLIT studies (n=24) a RR 
of 1.31(95%CI: 1.05, 1.63).(Figures S3e and f)   
 
We were able to pool data for the number of patients experiencing a systemic AE for SCIT and SLIT 
RCTs (n=18) to give a RR of 2.37 (95% CI: 1.09, 5.16). (Figure S3g) 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Local adverse events 
We were able to pool data for local AEs for 39 SCIT and SLIT RCTs to give an overall RR of 
experiencing a local AE of 1.78 (95%CI 1.51, 2.11).(Figure S3h) For SCIT studies (n=9), we found an RR 
of 2.21 (95%CI 1.43, 3.41) of experiencing a local AE and for SLIT studies (n=30) an RR of 1.71(95%CI 
1.43, 2.05).(Figures S3i and j)   
We were able to pool data for the number of patients experiencing a local AE for SCIT and SLIT RCTs 
(n=17) to give a RR of 1.72 (95% CI:1.32, 2.23) (Figure S3k) 
 
Case series  
Seven large case series were identified.(179–185) (Tables S2w-y) Local (LR) and systemic (SR) AEs were 
recorded in a range of treatment protocols, including conventional, rush, ultra-rush and cluster. In total 
4045 patients were included in these case series however only 3541 were patients with allergic 
rhinoconjunctivitis; we therefore focused on data for these patients.  
The case series were conducted in a number of countries including Spain, Colombia, US, Germany and 
Portugal.  
 
The case series highlighted that where modified allergen extracts were used to deliver AIT this was safer 
in terms of number of AEs reported compared to unmodified extracts. (180–183) 
 
Safety data from the rush (180) and ultra-rush (181,182) protocols were evaluated and are presented in 
Tables S2v and w. The studies concluded that the frequency of SRs were similar to conventional build-up 
schedules, but importantly rush and ultra-rush protocols were associated with improved patient 
adherence to treatment by reducing the number of injections required and the cost associated with 
treatment. Comparable benefits of cluster treatment protocol were also reported in one study. (184) 
Finally, one case series looked at investigating the number of AEs where patients received either 
conventional or cluster IT via the SLIT route. AEs were reported in 0.15% of all administered doses in 
which 9.3% of patients experienced a SR. The study concluded that SLIT was safe in the treatment of 
allergic rhinoconjunctivitis. (179) 
 
No fatalities were reported in any of these studies.  
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DISCUSSION  
Statement of principal findings 
This review of a very substantial body of international trial evidence, many of which were judged to be at 
low ROB, has found clear evidence that AIT improved all three of our primary outcomes – i.e. symptom, 
medication, and combined symptom and medication scores over the short-term. These findings were 
robust to pre-specified sensitivity analyses but evidence of potential publication bias was identified for all 
three primary outcomes.  Although the long-term studies are fewer in number, there was a modest 
evidence-base in support of the effectiveness of AIT in improving symptom scores after treatment 
discontinuation for both SCIT and SLIT. The evidence was less clear in relation to the impact on 
medication and combined symptom and medication scores. SCIT improved disease specific quality of life. 
We could draw no clear conclusions on the effectiveness  of AIT  on nasal and conjunctival challenges 
and on cost-effectiveness which may be cost-effective in an English NHS setting, but due to the poor 
quality of the studies this needs to be interpreted with caution. AIT increased the risk of adverse events 
for both SCIT and SLIT, but no fatalities occurred.  
 
Strengths and limitations 
To our knowledge, this is the most comprehensive assessment of AIT in allergic rhinoconjunctivitis ever 
undertaken.  We employed internationally accepted techniques to systematically identify, assess and 
synthesize a substantial body of evidence.  This involved taking advantage of and building on other recent 
systematic reviews focusing on distinct modes of delivering AIT.  
 
The limitations of this review need to be considered.  First, despite our extensive searches we may not 
have uncovered all relevant evidence on this subject.  Second, we were limited by the heterogeneity in 
approaches used to assess outcomes, which meant we were unable to pool data from all trials or 
undertake all the planned subgroup analyses.  Furthermore studies for which data was pooled also 
showed heterogeneity which may be related to the diverse populations studied, protocols followed, 
products used and duration of trial period. For the subgroup analyses that were undertaken, there was in 
some cases imprecision which impacted on our ability to draw clear conclusions. These subgroup analyses 
were indirect comparisons between SCIT and SLIT and the fidnings should therefore be cautiously 
interpreted. Third, because of the heterogeneity in scoring systems used, we undertook meta-analyses 
using random-effects modelling and pooled data using SMDs, which can be difficult to interpret.  The 
absolute size of the SMD was used to guide assessment of the likely effect size demonstrated.(186) 
Finally, it needs to be borne in mind that there may have been important differences in effectiveness 
between specific AIT products.  Investigating this issue was however beyond the scope of this review. In 
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terms of safety there was heterogeneity in reporting of adverse events with many differing scoring 
systems used due to this we were unable to report this outcome as originally planned using only the 
WAO grading system. 
 
Implications for policy, practice and research 
Our findings clearly show that AIT is effective in improving the three patient-reported outcomes that 
represented our primary outcomes, at least over the short-term, and that AIT should therefore be 
considered in the management of patients with allergic rhinoconjunctivitis.   
 
Greater standardization of trial designs and reporting techniques – in particular, in relation to choice of 
outcomes and their reporting so as to facilitate evidence syntheses and key subgroup analyses, would 
greatly help to advance the research base underpinning AIT. We therefore appreciate initiatives of the 
EAACI in e.g. harmonizing and standardizing clinical endpoints in AIT (187)  or determining threshold-
level of relevant pollen seasons for assessing clinical effect sizes. (188) We also wish to highlight the need 
for additional studies focusing on long-term outcomes and on studies of ILIT and other novel modes of 
delivery.   We hope that future researchers will build on the findings from this systematic review and aim 
to fill key evidence gaps and areas of continuing uncertainty. 
 
The findings from this review will be used to inform the development of recommendations for EAACI’s 
Guidelines on AIT for Allergic Rhinoconjunctivitis.  
 
Conclusions 
AIT is effective in achieving clinically important short-term improvements in symptom, medication and 
combined symptom and medication scores.  There is a limited body of evidence on the longer-term 
effectiveness of AIT in improving symptom scores. 
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METHODS 
The methods have been reported in detail in our published protocol (12).  
 
Search strategy 
A highly sensitive search strategy was developed and validated study design filters were applied to search 
electronic bibliographic databases.   To retrieve randomized controlled trials (RCTs), we applied the 
Cochrane highly sensitive search strategy for identifying RCTs in MEDLINE.(16) We searched the 
following databases: Cochrane Library including, Cochrane Database of Systematic Reviews (CDSR), 
Database of Reviews of Effectiveness (DARE), CENTRAL (Trials), Methods Studies, Health 
Technology Assessments (HTA), Economic Evaluations Database (EED), MEDLINE  (OVID), 
Embase (OVID), CINAHL (Ebscohost), ISI Web of Science (Thomson Web of Knowledge), TRIP 
Database  (www.tripdatabase.com), Clinicaltrials.gov (NIH web), Clinical Trials Register 
(www.clinicaltrialsregister.eu) launched by the European Medicines Agency (EMA), Current controlled 
trials (www.controlled-trials.com), Australian and New Zealand Clinical Trials Registry 
(http://www.anzctr.org.au). To retrieve case series, we used the filter developed by librarians at Clinical 
Evidence: http://clinicalevidence.bmj.com/x/set/static/ebm/learn/665076.html  
 
The search strategy was developed on OVID MEDLINE and then adapted for the other databases. In all 
cases, the databases were searched from inception to October 31, 2015.   
 
Subgroup analyses 
Subgroup analyses were undertaken to compare: 
 Children <18 years versus adults ≥18 years; (this represented a change from our plans to 
compare young children versus adolescents versus adults, which was necessitated by data not 
being available in formats suitable to support the original planned subgroup analyses)  
 SCIT versus SLIT  
 AIT for seasonal versus perennial allergens 
 Modified allergen extracts (allergoids) versus unmodified allergen extracts in SCIT 
 Pre-seasonal (short term treatment) versus continuous treatment in SCIT  
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 Pre-/co-seasonal (short term treatment) versus continuous treatment in SLIT 
 Aqueous solutions versus tablets in SLIT. 
 
RESULTS  
Effectiveness  
Description of trials  
We identified 61 SCIT RCTs (reported in 63 papers) (19–81) including 6,379 patients, 71 SLIT RCTs 
(reported in 75 papers) ) (82–119,119–121,121–156) including 13,636 patients and two ILIT RCTs 
(157,158) including 56 patients (Tables 1a-c).  The overwhelming majority of trials only reported on 
short-term effectiveness (Tables 2a-c).  
 
SCIT 
The majority of trials were led by teams from the UK (n=11), followed by: France (n=7); Spain (n=7); 
Italy (n=6); Germany (n=5); USA (n=5); Canada (n=3); Poland (n=4); Denmark (n=2); Sweden (n=2); 
Germany and Austria (n=2); Austria, Denmark, France, Italy, Sweden (n=1); Austria, Spain, Germany, 
(n=1); Australia, Canada, UK and USA (n=1); Belgium and the Netherlands (n=1); India (n=1); Sweden 
and Germany (n=1), and Macedonia (n=1).  
 
The majority of studies included adult participants (n=42). Fifteen studies included participants of any age 
(i.e. children and adults) and one included children aged up to 18 years of age. Three studies did not 
report the age of the participants.  
 
The most common allergen administered in the included studies was: grass pollen(s) (n=28), followed by: 
weed pollens (n=19); tree pollens (n=16); HDM (n=6); molds (n=3); cat dander (n=2); dog dander 
(n=1); and storage mites (n=1).  
 
SCIT was performed with a single allergen (i.e. allergens from the same group e,g, grasses) in 55 studies 
and with multiple allergens (i.e. from different groups e.g. grass and tree pollens) in the remaining six 
studies.  In these trials, SCIT was compared with placebo (n=53), routine care (n=4) or active treatment 
(n=12); (there was more than one comparator arm in some studies). 
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SCIT was administered continuously in 27 studies, pre-seasonally in 19 studies, pre- and co-seasonally in 
11 studies, pre-seasonally and continuously in different arms in one study and co-seasonally in one trial. 
The remaining trials (n=2) did not report on timing of administration.  
 
The protocols used were: conventional (n=45); cluster (n=9); rush (n=8); semi-rush (n=1); and ultra-rush 
(n=1). Two studies uses both conventional and cluster, and a further study used both rush and 
conventional protocols.  
 
The duration of treatment was heterogeneous, ranging from a single injection to four years. It was 
unclearly reported in one study and not reported at all in another trial.  
 
Short-term effectiveness of SCIT was assessed by symptom scores (n=51), medication scores (n=46) and 
combined symptom and medication scores (n=20).  Long-term effectiveness of SCIT was assessed by 
symptom scores (n=1) and medication scores (n=1), and combined symptom and medication scores 
(n=1).  
 
See Tables 1a and 2a for further details. 
 
SLIT 
The majority of studies were carried out in: multiple European countries (n=16); Italy (n=12);  Germany 
(n=7); France (n=6); Poland (n=4); US (n=3); Spain (n=3); the Netherlands (n=3); Austria (n=2); Canada 
(n=2); UK (n=2); Austria, Canada, Denmark, France and Germany (n=1); Brazil and the US (n=1); 
Canada and the US (n=1); China (n=1); Cyprus, Turkey and the UK (n=1); Czech Republic (n=1); 
Finland (n=1); Iran (n=1); Japan (n=1); South Africa (n=1); and Turkey (n=1).  
 
The majority of studies were in adults (n=28), followed by children up to the age of 18 (n=25) and 
studies conducted in both adults and children (n=17), one study did not report the age of the 
participants.(40) 
 
The major allergen type used in the immunotherapy was: was grass pollen(s) (n=40), followed by: 
HDM(s) (n=15); weed pollens (n=7); tree pollens (n=4); molds (n=3); and cat dander (n=2).  
 
SLIT was performed with a single allergen in 67 studies and with multiple allergens in four studies.  It was 
most commonly administered in the form of drops/solution (n=46), followed by tablets (n=22) and 
spray (n=1); the mode of administration was not reported in two studies.  In relation to the 
drops/solution and tablet preparations, the SLIT was subsequently swallowed in 50 studies, expectorated 
in three studies and not reported in 18 studies. 
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SLIT was compared with placebo (n=67); routine care (n=1); or active treatment (n=5) (with some 
studies including more than one comparator).  
 
SLIT was administered preseasonal and co-seasonally in 22 studies, pre-seasonally in seven studies and 
co-seasonally in five studies. The remaining studies did not report on the season of administration.  
 
The duration of treatment varied from 28 days to four years.   
 
Short-term effectiveness was assessed by symptom scores (n=56), medication scores (n=44); and 
combined symptom and medication scores (n=9). Long-term effectiveness was assessed by symptom 
scores (n=4), medication scores (n=2) and combined symptom and medication scores (n=2). 
 
See Tables 1b and 2b  for further details.  
 
ILIT 
The two ILIT trials were conducted in Switzerland and Sweden. They both investigated single allergen 
therapy, delivered through a cluster protocol to cat, and grass or birch pollen versus placebo. One used a 
pre-seasonal administration and the other continuous.  
 
Both trials reported on the short-term effectiveness by symptom scores and one reported on medication 
scores.   
 
See Tables 1c and 2c for further details. 
 
Primary outcomes 
Data on primary outcomes are summarized in Tables 4a-c .   
 
Symptom scores 
Long-term effectiveness 
In order to investigate long-term effectiveness, a number of investigators studied a discontinuation period 
following trials that involved randomization to AIT or placebo in which the superiority of AIT was 
confirmed.  In this longer-term phase, patients were followed-up and outcomes were then again assessed 
at least one year post-discontinuation of AIT.  
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There were four trials that studied this outcome, one SCIT and three SLIT, all of which were judged to 
be at low ROB.  Meta-analysis of data was not possible.  We therefore provide a descriptive summary of 
the main findings. 
 
A trial by Durham (1999) studied discontinuation of SCIT in grass pollen allergic patients.(42) 
Participants had previously participated in a one year RCT in which they were randomized to SCIT or 
placebo, which confirmed the superiority of SCIT. (42) All patients were then given SCIT for three years 
(i.e. four years in total for the trial intervention arm).  They were then randomized to receive either 
maintenance grass pollen SCIT or placebo injections for an additional three years.  The authors found no 
significant difference in symptom scores between the two groups and concluded that the initial 
three/four years of AIT had induced prolonged clinical remission.  
 
A five year double blind placebo controlled RCT by Durham (2012) had a three year SLIT tablets or 
placebo treatment period in grass pollen allergic patients followed by a two year blinded observation 
period when no active treatment was administered.(114) Two years after discontinuing treatment, the 
group who had received SLIT were found to have a significant improvement in symptom scores when 
compared to placebo (P<0.004). 
 
Bergmann (2013) followed patients for one year after discontinuing one year of HDM SLIT at two 
different doses (300 IR or 500 IR) compared with placebo, which found that the active treatments 
significantly improved symptom scores.(89) One year after discontinuing AIT, the symptom 
improvements in the SLIT arms were maintained when compared to placebo.  
 
Ott (2009) conducted a four year study which randomized patients to three years of seasonal grass pollen 
SLIT or placebo, followed by a one year discontinuation phase.(133) They found that improvements in 
symptom scores were maintained in the SLIT group after treatment was discontinued (P=0.015).  
 
In summary, all four trials at low ROB found a beneficial effect on the long-term effectiveness of AIT on 
symptom scores.  
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Sensitivity and subgroup analyses and assessment of publication bias 
These analyses were not possible. 
 
 
Medication scores 
Long-term effectivenss  
There were three low ROB trials that assessed this outcome: one SCIT and two SLIT.  These three trials 
are all described in more detail above when discussing long-term effects on symptom scores. 
 
The trial by Durham (1999) in grass pollen allergic patients found that in the discontinuation RCT there 
was no significant difference between patients who continued SCIT when compared to those who 
received placebo.(42) 
 
Another trial by Durham (2012) found that two years after discontinuing SLIT there was no difference in 
medication scores between those who had previously received SLIT compared to those who received 
placebo.(114) 
 
Ott (2009) found that one year after completion of a trial of three years of seasonal grass pollen SLIT or 
placebo there was no significant improvement in medication scores (P=0.84).(133) 
 
Overall, one trial found a benefit of AIT (SCIT) on long-term medication scores; the two other SLIT 
trials did not show a sustained effect.   
 
Combined symptom and medication scores 
Long-term effectiveness  
We found one SCIT trial and two SLIT trials that reported on this outcome.   
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The trial by James (2011), at low ROB, studied grass allergic patients who were randomized to two years 
of SCIT or placebo.(53) They were randomized to receive SCIT or placebo injections during the initial 
trial, which found a benefit from SCIT.  Those in the active arm were then randomized to a further two 
years of SCIT or placebo and this found low combined symptom and medication scores in both arms, 
similar to the scores at the end of the initial trial. The authors concluded that clinical tolerance was 
maintained for at least two years after discontinuation of AIT.  
 
Ott (2009; described above), at low ROB, failed to find a significant difference in long-term combined 
symptom and medication scores following discontinuation of SLIT grass pollen treatment 
(P=0.052).(133) 
 
Didier (2013) conducted a  four year study, at unclear ROB, in which they randomized grass pollen 
allergic patients to SLIT commencing either four months pre-seasonally or two months pre-seasonally 
(i.e. two active groups) or placebo for three consecutive seasons.(109) This showed that both active 
treatment arms were beneficial in improving combined symptom and medication scores.   They then 
continued to monitor patients for an additional fourth year (during which they did not receive SLIT or 
placebo), which found that the average adjusted symptom score (i.e. combined rhinoconjunctivitis 
symptom and medication score) was significantly improved in the SLIT groups when compared to 
placebo (two months pre-seasonal: P=0.0019; four months pre-seasonal: P=0.01) A further post-hoc 
analysis of this trial, was conducted at year five – i.e. two years after discontinuing AIT – and significant 
improvement was demonstrated in the four months group compared to placebo (P=0.047), but not in the 
two month preseasonal group.(159) 
 
Overall, one of the three trials found evidence of a sustained beneficial effect on combined symptom and 
medication scores. The one trial at an unclear ROB (Didier 2013/2015) demonstrated a two year carry 
over effect of AIT in the active SLIT group that received AIT four months pre-seasonally for three 
consecutive seasons but not for the group which received AIT two months pre-seasonally. 
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Scondary outcomes 
Allergen challenge models in AIT 
The data for these outcomes were not reported in a format suitable for undertaking meta-analysis. We 
therefore provide a narrative description below with a focus on those trials judged to be at low risk of 
bias (ROB). 
 
Environmental exposure chamber  
Four studies were conducted with the use of an Allergen Exposure Challenge (AEC): one using SCIT and 
three SLIT. Two were for cat allergy one for grass pollen and one for birch pollen.  
 
The SCIT study by Patel (2012) was judged to be at low ROB.(65) This exposed cat allergic patients to 
allergen at baseline and at 22 weeks and 52 weeks after treatment with a short course of FelD1-derived 
peptide antigen SCIT (CatPad) using two different dosing regimens (8x3nmol or 4x6 nmol). Each 
assessment was undertaken over four consecutive days with three hours exposure to allergen in the EEC. 
Total rhinoconjunctivitis symptom scores (TRSS) were measured at these assessments. At the assessment 
at 50-54 weeks, the higher dose (4x6 nmol) treated patients had a significantly improved TRSS score 
compared to placebo (P=0.01), but the lower dose group did not (P=0.74). 
 
The high ROB SLIT study with natural cat extract by Alvarez Cuesta (2007) involved a natural exposure 
challenge (NCT) to cat allergen in a cat room before and after treatment.(83) There was a significant 
improvement with SLIT compared to placebo (P<0.001). The remaining two SLIT studies used the 
Vienna Challenge Chamber (VCC). The SLIT study by Horak 1998 for birch pollen administered AIT for 
28 days followed by a three-month maintenance period VCC measurements of nasal air flow were taken 
at baseline and at the end of the maintenance period which demonstrated a significant improvement in 
the active group. (P=0.03)(120) The Horak 2009 study of 5 grass pollen SLIT showed the active group 
had a significantly lower average rhinoconjunctivitis symptom score than the placebo group after four 
months of treatment (P=0.0003)(121) 
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All of these studies thus demonstrate the effectiveness of AIT in an environmental exposure chamber.  
 
Nasal challenge 
Twenty-six studies performed nasal allergen challenge tests, 15 SCIT (23,24,27,29,30,33,37,43,52,57–
59,63,64,75) and 11 SLIT (Table 1a).(84,86,87,92,93,122,128,136,139,146,150).  
 
SCIT trials  
Of the 15 SCIT studies, eight showed a significant improvement in the SCIT group compared to placebo 
(24,27,29,37,43,52,58,75) and four showed no significant difference between the active and control 
groups. (23,33,57,59) The remaining three studies did not report a between group comparison, but both 
reported an improvement in the active group with a higher threshold of reactivity to allergen and no such 
change in the control group.(63,64,160) 
 
Nine SCIT studies were at low ROB; of these four showed no significant difference between SCIT and 
control groups (23,33,57,59) and three studies showed a significant difference between active and control 
groups. (29,37,43) The remaining two studies did not report a between group comparison, but both 
reported a higher allergen threshold of reactivity in the active group and no such improvement in the 
control group.(63,64) 
 
SLIT trials 
Eleven SLIT studies reported on this outcome of which three studies showed no significant difference 
between active and control groups (87,128,146) and five studies showed a significant reduction in nasal 
reactivity in the SLIT group compared to controls.(86,93,122,139,150) Of the remaining three studies, 
two reported no between group data (92,136) and the other had two active groups: the single allergen 
SLIT group had a significant difference between placebo in nasal reactivity, but this was not the case for 
the multiple allergen SLIT group.(84) 
 
Of these, three SLIT studies were at low ROB with variying conclusions. The Amar (2009) study showed 
a significant improvement in the single allergen SLIT group, but not in the multiple allergen group 
compared to placebo (P=0.03 and P=0.11, respectively).(84)  Aydogan (2013) showed no significant 
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improvement in the SLIT group compared to placebo following one year of house dust mite (HDM) 
SLIT (P>0.05).(87) Finally, Hirsch (1997) demonstrated a significant improvement in PC40 nasal flow in 
the SLIT group compared to placebo (P<0.05).(122) 
 
Nasal challenge: Overall interpretation 
Due to the conflicting results from higher quality SCIT and SLIT trials it is difficult to draw any clear 
conclusions in relation to this outcome.  
 
Conjunctival challenge 
Conjunctival challenges were undertaken in 16 studies: SCIT (n=12) (21,23,35,38,42,45,55,62,63,70,72,77) 
and SLIT (n=4) (Table 1b).(120,127,138,146) 
 
SCIT studies 
Of the 12 SCIT studies that reported on this outcome, one showed graphical information only (62) and 
four reported no between group results.(38,63,72,112) These studies will therefore not be considered 
further. Of the remaining seven studies, five showed no significant improvement in conjunctival 
provocation tests (CPT) between active and control groups(21,23,45,55,70) and two showed an 
improvement.(35,77) 
 
Concentrating on the five low ROB SCIT studies, four studies showed no significant improvement in 
CPT in the SCIT group compared to control (21,23,45,70) whereas one demonstrated an 
improvement.(77) 
 
SLIT studies 
Four SLIT studies reported on this outcome: two were at high ROB (127,146) and two at an unclear 
ROB.(120,138) Two studies demonstrated a significant improvement in CPT in the SLIT group 
compared to placebo (127,138) one reported no significant improvement(146) and one reported no 
between group comparison. (120) 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Conjunctival challenge: Overall interpretation  
Four SCIT studies of high quality demonstrated that AIT is not effective in improving conjunctival 
provocation to allergen. There were no high quality SLIT studies that reported on this outcome, which 
makes it difficult to draw any firm conclusions.  
 
Cost-effectiveness 
Characteristics of studies   
We identified 19 eligible studies that reported on health economic evaluations of SCIT and SLIT in both 
children and adults (Table 2).(160–178) Two of these 19 studies focused on patients who all had both 
allergic rhinitis and allergic asthma(177,178)   and the remaining 17 focused on patients who had allergic 
rhinitis, some of whom also had asthma.  
 
Three of these studies reported results solely from a societal perspective (160,161,180) with the other 16 
reporting information from a health systems perspective. 
 
Studies were based in a range of countries: Germany (n=7), Denmark (n=4), Italy (n=4), UK (n=4), 
Austria (n=2), Finland (n=2), France (n=2), the Netherlands (n=2), Sweden (n=2), Canada (n=1), Czech 
Republic (n=1), Norway (n=1) and Spain (n=1). Three studies reported results for more than one of 
these countries.  
 
Seven of the studies reported results against disease specific outcome measures whilst the remaining 12 
reported results based on quality adjusted life years (QALYs). 
 
Thirteen of the studies were based on RCT data or meta-analyses of RCT data (160–169,176–178) 
including two model based evaluations (165,169) with the remaining studies being based on a mixture of 
questionnaires, observation data and expert opinion. None of the studies based on non-random data 
attempted to control for selection bias. None of the RCT-based studies described the amount of missing 
data in the study or explained how if at all any missing data were imputed for in the analyses. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Study time horizons ranged between one year and 15 years with the longer time horizon studies, of which 
the last were typically based on much shorter follow-up trial data (typically one year) and assuming 
constant continued treatment effect even after treatment was discontinued. 
 
Nine of the studies compared SLIT versus standard care,(161,163,169,166–171,177,178) three studies 
compared SCIT versus standard care,(162,169,172) two studies compared AIT (undefined) versus 
standard care,(173,175) seven studies compared SCIT versus SLIT (160,165,167–169,174,176) and of 
these two studies compared different SLIT treatments.(165,167)  
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Bozek, 2016, 
Poland 
X        X  X   X   X     3 y Pollen mixture extract solution of grass pollens 
(Agrostis stolonifera, A odoratum, Arrhenatherum 
elatius, D glomerata, Festuca rubra, Holcus lanatus, 
Lolium perenne, P pratense, P pratensis, Secale cereal, 
and Loe edasi) / Purethal grasses ( HAL Allergy 
BV) 
X X X    X X 
Brunet, 1992, 
Canada 
  X      X  X   X   X     3 
m 
Alum-precipitated aqueous ragweed extracts / 
NR 
X X     X  
Ceuppens, 
2009, 
Belgium & 
the 
Netherlands 
 X       X  X     X X     18 
m 
Glutaraldehyde-modified birch pollen extract 
adsorbed onto aluminium hydroxide 
/PURETHAL® Birch 
  X    X  
Chakraborty,  
2006, India 
 X       X  X     X X     2 y Phoenix sylvestris Roxb or sugar palm allergoid 
extract / NR 
  X    X  
Charpin,  
2007, France 
 X       X  X     X X     15 
m 
Standardized, aluminum hydroxide-adsorbed 
Juniperus ashei extract/ Alustal® (Stallergenes) 
X X     X X 
Colas, 2006,   X      X  X     X  X    1 y Depigmented and glutaraldehyde polymerized 
extract of Salsola kali absorbed onto aluminium 
X X     X X 
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Spain hydroxide/ NR (supplied by Laboratorios LETI, 
SL.) 
Corrigan, 
2005, UK 
X        X  X   X   X     2 y Aluminium-adsorbed six-grass pollen allergoid / 
Allergovit® 
X X     X X 
Crimi,  2004, 
Italy 
  X      X  X     X  X    3 y Intact Parietaria judaica extract  adsorbed onto 
aluminum hydroxide / Alutard SQ® 
X X     X  
Dokic,  2005, 
Macedonia 
    X    X  X      X     3 y Aluminium hydroxide adsorbed D.pt. allergoid / 
NR (Allergopharma) 
X X     X  
Dolz, 1996, 
Spain 
X        X  X     X    X  3 y Grass-pollen allergen extract (Phleum, Dactylis, 
Lolium) adsorbed onto aluminum hydroxide / 
Alutard SQ® (ALK-Abelló) 
X X     X  
Drachenberg
, 2001, 
Germany 
and Austria 
X        X  X   X   X     4-
7 
w 
Tyrosine-adsorbed glutaraldehyde-modified grass 
pollen extract containing monophosphoryl lipid 
A as adjuvant / Pollinex Quattro ® 
X X X    X  
Drachenberg
,   2002, 
 X       X  X   X   X     4-
7 
L-tyrosine-adsorbed birch, alder, hazel pollen 
allergoids treated with glutaraldehyde plus 
  X    X  
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Germany  w monophosphoryl lipid-A (MPL) / Pollinex 
Quattro ® 
DuBuske, 
2011, USA, 
Canada, UK, 
Austria 
X        X  X   X   X     4-
8 
w 
Modified Allergen Tyosine Adsorbate (MATA) 
consisting of a mixture of modified pollen 
allergens from 13 grass species adsorbed onto 
tyosine/ Pollinex Quattro, Pollinex 
Complete; Allergy Therapeutics, U.K. 
  X    X  
Durham , 
1999, UK 
Primary 
study 
Varney, 1991 
X        X  X  X   X X     3 y Standardized, aluminum hydroxide–adsorbed, 
depot grass pollen vaccine / Alutard SQ® (ALK 
Abelló) 
   X X  X  
Ewan  , 
1988, UK 
    X    X  X        X   3 
m 
Partially purified extract of D. pteronysinus / 
Pharmalgen® 
X      X  
Fell,  1988, 
UK 
X        X  X   X       X 1 
inj
ect
io
Enzyme (glucuronidase) potentiated  grass pollen 
allergens / (Pharmacia) 
X X       
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n 
Ferrer, 2005, 
Spain 
  X      X  X     X X     20 
m 
Biologically standardized extract of Parietaria 
judaica adsorbed onto aluminium hydroxide gel / 
Pangramin ®Depot, ALK-ABELLÓ 
X X X    X X 
Frew, 2006, 
UK 
X        X  X  X X X  X     1 y Standardized depot preparations of grass pollen 
extract / Alutard SQ grass pollen® (ALK-
Abello´) 
X X     X X 
Grammer, 
1982, USA 
  X      X  X X  X   X     15 
w 
Polymerized ragweed extract (PRW)/NR X      X  
Grammer, 
1983, USA 
X        X  X   X   X     4 
m 
Six grass pollen allergoid prepared by 
polymerization with glutaraldehyde / NR 
X X     X  
Grammer, 
1984, USA 
  X      X  X X  X   X     >3
0 
m 
(U
R) 
Polymerized ragweed  extract / NR   X   X X  
Grammer, X        X  X   X   X     4 Polymerized ragweed  extract / NR   X    X  
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1987, USA m 
Höiby,  
2010, 
Sweden & 
Germany 
 X       X  X     X X     18 
m 
Depigmented polymerized birch pollen  (Betula 
alba) extract adsorbed onto aluminium 
hydroxide/ Depigoid ®(Laboratorios LETI Sl) 
  X    X  
Horst, 1989, 
France 
   X     X  X     X    X  1 
ye
ar 
lyophilized and standardized Alt extract  
Stallergnes Laboratories 
  X    X  
Iliopoulos, 
1991, USA 
  X      X  X   X X  X     ~8 
m  
Short ragweed extract / NR (Greer 
Laboratories,Lenoir, N.C.) 
  X    X  
James, 2011, 
UK 
X        X  X     X X     2/
4 y 
Phleum  pratense extract adsorbed with aluminum 
hydroxide /  Alutard SQ ® 
   X  X   
Juniper,  
1990, Canada 
  X      X   X  X X  X     6 
w  
Modified ragweed tyosine adsorbate / Pollinex® 
(Bencard Allergy Service) 
X X     X  
Jutel,  2005, 
Poland  
X        X  X   X X  X     8-
9 
m 
Five recombinant grass pollen allergens / NR 
(Allergopharma) 
  X    X X 
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Kleine-
Tebbe, 2014, 
Spain, 
Germany & 
Austria 
X        X  X  X   X X     1 y Aluminium hydroxide adsorbed Phleum pratense 
extract /  AVANZ ® Phleum pratense (ALK) 
X X     X  
Klimek, 
2014, 
Germany  
X  X       X X   X X   X    1 y Glutaraldehyde-modified high polymerized 
allergen extract containing 6 grasses (60%) and 
rye pollen adsorbed onto aluminum hydroxide / 
CLUSTOID® (ROXALL Medizin) 
X X X    X  
Kuna, 2011, 
Poland 
   X     X  X     X X     3 y Alternaria alternata extract in a depot formulation 
with aluminum hydroxide / Novo-Helisen Depot 
® A alternata 100% (Allergopharma) 
X X X    X X 
Leynadier,  
2001, France 
X        X  X     X X     1 y Standardized five-grass-pollen (equal parts of: 
orchard, meadow, rye, sweet vernal and timothy) 
depot extract adsorbed onto calcium phosphate / 
Phostal® (Stallergenes) 
X X X    X  
Metzger, 
1981, 
England 
  X      X  X   X   X     5 
w 
Glutaraldehyde-modified, tyosine-adsorbed short 
ragweed extract / NR (Beecham Laboratories) 
X      X  
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Mirone ,  
2004, Italy 
  X      X  X     X X     1y 
(D
B
R
C
T) 
Ambrosia artemisiifolia absorbed onto aluminium 
hydroxide and suspended in phenolated (0.4% 
w/v) saline solution / NR (ALK-Abello`) 
X X     X  
Olsen,  1995, 
Denmark 
X X X       X   X   X X     2 y Aluminium hydroxide adsorbed extracts of 
standardized extracts of Betula, Phleum and  
Artemisia / Alutard® SQ (ALK) 
X      X  
Ortolani, 
1994, Italy 
  X      X  X     X X     1 y Partially purified alginate-conjugated extract of 
Parietaria judaica / Conjuvac Parietaria ® (Dome 
Hollister-Stier) 
  X    X  
Pastorello, 
1992, Italy  
X        X  X   X X  X     5-
12
m  
Formalinized depot 6 grass  allergoid  absorbed 
onto aluminum hydroxide / NR (Allergopharma) 
  X    X  
Patel,   2012, 
Canada  
     X   X  X  X     X    3 
m 
Fel d 1–derived peptide antigen (Cat-PAD) / NR 
(Bachem and Patheon) 
X*   X*   X  
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Pauli, 2008, 
Austria, 
Denmark, 
France, Italy 
& Sweden 
 X       X  X  X   X X     2 y Aluminum hydroxide–adsorbed vaccines of birch 
pollen extract, rBet v 1, and nBet v 1 / NR 
(Stallergenes SA) 
X X     X  
Pfaar, 2010, 
Lithuania, 
Poland & 
Germany 
 X       X  X     X X     19 
m 
Standardized depigmented and glutaraldehyde-
polymerized tree pollen extract (33% Corylus 
avellana, 33% Alnus glutinosa, 34% Betula alba) 
adsorbed onto aluminium hydroxide / 
Depigoid(Laboratorios LETI SL, Tres Cantos, 
Spain), 
X  X    X  
Pfaar, 2011, 
Germany 
X        X  X   X      X  2 y Depigmented and glutaraldehyde-polymerized 
grass pollen mix adsorbed onto aluminum 
hydroxide /  Depiquick®  (Laboratorios LETI) 
X X X    X X 
Powell, 2007, 
UK 
Primary 
study Frew, 
2006 
X        X  X  X   X X     14
m 
Standardized depot preparations of grass pollen 
extract / Alutard® SQ grass pollen (ALK-
Abello´) 
       X 
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Radcliffe ,  
2003, UK 
X X X X X X X X  X X   X        2-
3 
m 
Enzyme potentiated mixed inhaled allergen 
extract (pollen mixes for trees, grasses, and 
weeds; allergenic fungal spores; cat and dog 
danders; dust and storage mites) / NR 
X      X X 
Rak,  2001, 
Sweden  
 X       X   X  X    X    1 y Birch pollen extract adsorbed onto aluminum / 
Alutard® (ALK-Abelló) 
X X       
Riechelmann
, 2010,  
Germany & 
Austria  
 
 
   X    X  X     X X     1 y Single-strength glutaraldehyde-modified 
aluminum hydroxide–adsorbed extract / HDM 
PURETHAL Mites ® (HAL-Allergy) 
X X     X X 
Tabar, 2005, 
Spain 
    X    X    X    X X    1 y Biologically standardized HDM depot extract 
adsorbed on aluminum hydroxide / Pangramin 
Depot UM D pteronysinus® (ALK-Abello´) 
X X     X  
Tabar, 2008, 
Spain 
   X     X  X     X X     18 
m 
Metabolic extract of Alternaria alternata /  
Allergovac® depot 
X X     X X 
Tari, 1997, 
Italy 
  X      X  X     X X     2 y Alum-adsorbed Parietaria judaica pollen allergoid/ 
Allergovit® (Allergopharma) 
X X     X  
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Tworek, 
2013, Poland 
X  X       X   X X  X X     3 y Allergoid preparation consisting of 80% grass 
pollen and 20% rye pollen extracts / Allergovit® 
(Allergopharma) 
X X X    X  
Varney, 
1991, UK 
 X       X  X   X X  X     8 
m 
Partially purified and standardised extract of 
Phleum pratense adsorbed onto aluminium / 
Alutard SQ® (ALK-Abelló) 
X X     X  
Varney, 
2003, UK  
    X    X       X X     1 y Intact HDM extract vaccine adsorbed onto 
aluminum hydroxide/ Alutard SQ® (ALK-
Abelló) 
X X     X  
Walker,  
2001, UK 
X        X  X     X  X    2 y Alutard SQ (ALK Abelló, Horshølm, 
Denmark), a standardized extract of Phleum 
pratense (timothy 
grass pollen),7 aluminum adsorbed for slow 
release 
X X     X X 
Weyer,  
1981, France 
X        X  X   X   X     8 
m 
Crude 4 grass pollen extract / NR X X X    X  
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Zenner,  
1997, 
Germany  
X  X      X  X    X  X     4 
m 
Partially purified and standardized extracts  of  6 
grasses (50%, Dactylis glomerata, Lolium perenne, 
Arena elatior, Phleum pratense, Poa pratensis, and 
Fetuca pratensis) and rye, (50%, Secale cereale) 
adsorbed onto aluminum hydroxide / NR 
(manufactured by ALK A/S ) 
X X     X  
AIT, allergen specific  immunotherapy; m, month; NBS, not better specified;  NR, not reported;  Rx, treatment; SCIT, subcutaneous immunotherapy; SLIT, sublingual 
immunotherapy; UR, unclear reporting w, week; y, y. 
*environmental exposure chamber 
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Ahmadiafshar, 
2012, Iran 
X        X  X   X X      X 6 
m 
10, 100, and 300 IR rye grass 
spray (Staloral 638) 
X X     X  
Alvarez-Cuesta, 
2007, Spain 
     X   X  X           12 
m 
Aqueous solution of cat dander 
extract with NaCl 0.9%, phenol 
0.4% and glycerol 50% (protocol 
supplied by Laboratorios LETI, 
S.L. 
X      X  
Amar, 2009, US X         X X  X   X      10 
m 
Monotherapy group: timothy 
extract 
Multiple allergen group: same 
amount of timothy plus 1 mL 
each of 
an additional 9 unstandardized 
extracts 1:20 wt/vol in 50% 
glycerin: maple, 
ash, juniper, American elm, 
cottonwood, Kochia, ragweed, 
sagebrush, and 
Russian thistle (ALK-Abello´). 
X X     X  
André, 2003, 
France 
  X      X  X    X       6.5 
m 
standardized ragweed extract 
(Stallergènes SA, Antony, 
France)  
X X     X  
Ariano, 2001, 
Italy & France 
 X       X  X     X      12 
m 
Aqueous solution of an allergic 
fraction of Cupressus arizonica 
partially purified through dialyis 
in a phyiological solution 
with 15% glycerin. 
X X     X  
Aydogan, 2013, 
Turkey, UK & 
Cyprus. 
    X    X  X           12 
m 
1:1 mixture of D. pteronysinus and 
D. farinae (STALORAL, 
Stallergenes SA, Antony, France)  
X X       
Bahçeciler, 
2007, 
 Turkey 
    X    X  X           6 
m 
D. pteronysinus and D. farinea 
50/50 extract. 
X        
Bergmann, 
2013, Germany, 
France, the 
Netherlands & 
Spain 
    X    X  X           2 y Oral tablets of 1:1 mixture of D 
pteronysinus and D farinae (28 mg 
and 120 mg respectively for the 
500 IR tablet, 16 mg and 68 mg 
respectively for the 300 IR 
tablet)  
X   X   X  
Blaiss, 2010, US 
& Canada 
X        X  X           18 
m 
f 2,800 bioequivalent allergen 
units of grass AIT treatment 
(oral lyophilisate, Phleum pratense, 
75,000 standardized quality 
tablet, containing approximately 
15 mg of Phl p 5; Schering-
Plough Corp, a division of 
Merck & Co, Kenilworth, NJ)  
X X X    X X 
Bowen, 2004,   X      X  X   X        4 Ragweed allergen extract  X X     X  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Canada m 
Bozek, 2012, 
Poland 
    X    X  X           3 y Oral Staloral 300 SR Der p and 
Der f (1:1)  
X X     X  
Bozek, 2014, 
Poland 
X        X  X           3 y Oral Staloral 300 SR 5 grass 
pollen solution of P. pratense, D. 
glomerata, A. odoratum, L. perenne, 
and P. pratensis (Stallergenes) 
X X     X  
Bufe, 2004, 
Germany 
X        X  X    X       3 y Grass pollen extracts (Sublivac 
B.E.S.T.TM, HAL-Allergy, 
Haarlem, the Netherland) 
        
Bufe, 2009, 
Germany 
X        X  X   X X       8-
23 
w 
Orodispersible, fast-dissolving, 
SQ-standardized grass allergen 
tablet (Grazax; ALK, Hørsholm, 
Denmark; 75,000 SQ-T/2800 
bioequivalent allergen units, 
approximately 15 mg Phl p 5, 
Phleum pratense major allergen 
5) 
X X     X  
Caffarelli, 2000, 
Italy 
X        X  X   X        3 
m 
Mixture of monomeric  grass-
pollen allergens (33% Holcus 
lanatus, 33% Phleum pratense, and 
33% Poa pratensis) in tablets 
(LAIS, Lofarma S.p.A, Milan, 
Italy)  
X X     X  
Clavel, 1998, 
France 
X        X  X           7 
m 
Mixture of five major grass 
pollens (orchard grass, meadow 
grass, ryegrass, sweet vernal 
grass, and timothy grass 
X X     X  
Cortellini, 2010, 
Italy 
   X     X  X           10 
m 
Glycerinated Alternaria alternata 
extract in droplets (Anallergo, 
Firenze, Italy) 
X X     X  
Cox, 2012,  US X        X  X           6 
m 
300IR SLIT tablets containing a 
standardized 5-grass pollen 
allergen obtained by means of 
extraction of a mixture of 5 grass 
pollens in equal amounts 
(orchard grass, Dactylis glomerata; 
Kentucky bluegrass, Poa pratensis; 
perennial rye grass, Lolium 
perenne; sweet vernal grass, 
Anthoxanthum odoratum; and 
timothy grass, Phleum pratense) 
X X X    X X 
Creticos, 2013, 
US 
  X      X  X   X X       20 
m 
Short ragweed  tablets (1.5, 6, or 
12 units of Ambrosia artemisiifolia 
major allergen 1 [Amb a 1-U])  
X X X    X  
Creticos, 2013, 
Canada 
  X      X  X    X       12 
w  
ragweed SAIL (RW-SAIL) 
Standardized glycerinated short 
ragweed  
X  X    X  
Dahl, 2006, 
Denmark, 
Germany, Italy, 
the 
Netherlands, 
Sweden, 
Austria, Spain 
& UK 
X        X  X   X X       1 y Grass pollen allergen tablet 
(GRAZAX) (75,000 SQ-T; 15 
mg major allergen Phleum p 5)  
X X     X  
Dahl, 2006, 
Denmark & 
Sweden 
X        X  X   X X        Orodispersible grass allergen 
tablet  (GRAZAX; 
approximately 15 mg major 
allergen Phleum pretense (75 000 
SQ-T)  
X X     X  
de Blay, 2007, 
France 
X        X  X   X X       12 
m 
3-grass pollen extract (33.3% 
Dactylis glomerata [orchard grass], 
33.3% Phleum pretense timothy 
grass], and 33.3% Lolium perenne 
[rye grass]) Allerbio, Varennes-
en-Argonne, France) in 50% 
glycerin 
X X     X X 
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De Bot, 2011, 
The 
Netherlands 
    X    X  X           2 
yea
rs 
aqueous extract of house dust 
mites (D pter,) in a glycerinated 
isotonic phosphate-buffered 
solution (Oralgen Mijten) / 
placebo treatment consisting of 
the glycerol-containing solvent 
X X     X X 
Demoly, 2015, 
Europe 
    X    X  X           1 y 1:1 mixture of two species of 
house dust mite allergens (D. 
pteronysinus and D. farinae) (1:1:1:1 
ratio of the major allergens Der p 
1, Der f 1, Der p 2, and Der f 2)  
X X     X X 
Didier, 2007, 
Europe 
X        X  X   X X       6 
m 
Mixture of 5 grass pollens 
(orchard, meadow, perennial rye, 
sweet vernal, and timothy 
grasses)  
X      X X 
Didler, 2009, 
France, 
Germany & 
Spain 
X        X  X  X X X       6 
m 
Lyophilized vaccines of five 
grass pollens (orchard or 
cocksfoot (Dactylis glomerata), 
meadow ( Poa pratensis), perennial 
rye (Lolium perenne), sweet vernal 
(Anthoxanthum odoratum) and 
timothy (Phleum pratense))  
X      X  
Didier, 2013, 
Denmark, 
Austria, France, 
Canada & 
Germany 
X        X  X   X X       4 y 300IR  tablets containing 
mixture of 5 grasses [cocksfoot 
(Dactylis glomerata), meadow (Poa 
pratensis), rye (Lolium perenne), 
sweet vernal (Anthoxanthum 
odoratum) and timothy (Phleum 
pretense)  
X      X X 
Durham, 2005, 
Canada, 
Denmark & 
Sweden 
X        X  X   X X       2 y Fast-dissolving grass allergen 
tablet (ALK-Abello A/S) 
containing timothy grass extract 
(Phleum pratense)  
X X     X X 
Durham, 2007, 
UK 
Primary study: 
Dahl, 2006 
X        X  X           16 
w 
Grass allergen tablet (Grazax)         
Durham, 2009, 
UK 
Results after 1 y 
follow-up of 
Dahl, 2006 
study 
X        X  X   X X       3 y Grass allergen tablet with Phleum 
pratense 75,000 SQ-T/2,800 BAU 
(ALK-Abello´, Hørsholm, 
Denmark) (Grazax)  
        
Durham, 2011, 
UK 
Results of 2 y 
follow-up of 
Dahl 2006 trial  
X        X  X          X 2 y SQ-standardized grass allergy  
tablet (Phleum pratense 75 000 SQ-
T/2,800 BAU, ALK, Denmark) 
(Grazax)  
      X   
Durham., 2012, 
UK, Austria, 
Germany, the 
Netherlands, 
Sweden & 
Denmark      
Results of 2 y 
follow-up of 
Dahl 2006 trial 
X        X  X   X X       3 y SQ-standardized grass allergy  
tablet (Grazax)  
   X   X  
Drachenberg, 
2002, Germany  
X X        X X      X      Grass, rye or birch pollens X X X      
Feliziani, 1995, 
Italy 
X        X  X   X X     X   Grass pollen extracts (5 x 1 drop 
of 0.04 BU/ml, up until 5 x 1 
drop of 100 BU/ml)  
X X     X  
Frølund, 2010, 
Austria, 
Denmark & 
UK 
X        X  X   X X       4 y SQ-standardized grass allergy 
immunotherapy tablet (AIT), 
Grazax (Phleum pratense 75,000 
SQ-T/2800 BAU; ALK, 
Denmark).  
       X 
Guez, 2000,     X    X  X           24 D. pteronysinus and D. farinae X X     X  
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France m 50/50 extract 
Halken, 2010, 
Germany, 
Denmark, 
Poland, France 
& Spain 
X        X  X   X X       10 
m 
five-grass pollen 300IR tablets 
(Stallergènes SA, France)  
X      X  
Hirsch, 1997, 
Germany 
    X    X  X           12 
m 
Purified D. pteronysinus extract in 
50% aqueous glycerol 
(cumulative dose 570 jag) 
(Allergopharma J. Ganzer KG, 
Reinhek, FRG)  
X X       
Horak, 1998, 
Austria 
 X       X  X           4m Biologically standardized Betula 
Alba Alergia e Immunologia 
Abello SA 
X      X  
Horak, 2009, 
Austria 
X        X  X           4m 300-IR 5 grass pollen tablet 
(orchard, meadow, perennial rye, 
sweet vernal, timothy) 
X      X  
Hordijk, 1998, 
the Netherlands 
X        X  X    X       10 
m 
Glycerinated (50% w/v) five-
grass pollen extract 
(Anthoxanthum odoratum (Sweet 
vernal grass), Cynodon dactylon 
(Bermuda grass), Dactylis 
glomerata (Orchard grass), Holcus 
lanatus (Velvet grass) and Phleum 
pratense (Timothy grass)) (9,500 
BU/ml) (Oralgen) (ARTU 
Biologicals Europe B.V., 
Lelytad, The Netherlands)  
X      X  
Ibanez, 2007, 
Spain & 
Germany 
X        X             28 
d 
Orodispersible grass allergen 
tablet (75,000 SQ-T; 15 Ig P. 
pratense major allergen (Phl p 5)) 
(Grazax) ALK-Abello A/S, 
Horsholm, Denmark)  
      X  
Ippoliti, 2003, 
Italy 
    X    X  X           6 
m 
D. pteronysinus extract  X        
Kaluzinska-
Parzyzek , 2011, 
Poland (Polish, 
translated) 
 
X        X  X   X X   X    2 y Staloral 300 IR (Stallergenes)          
La Rosa, 1999, 
Italy & France 
  X      X  X           2 y P judaica extract (Stallergènes, 
Antony, France) in drops  
X X     X  
Marcucci, 2003, 
Italy 
    X    X  X           1 y house dust mite allergens (1 ml 
of the top-dose vial 1000 
STU/ml/4 lg of the major mite 
allergen Group 1 and 2 lg of the 
major mite allergen Group 2) 
        
Moreno-
Ancillo, 2007, 
Spain 
X         X X   X X       10 
m 
2 μg of grass Group 5 and 3 μg 
of Olive europaea Ole e 1 (daily)  
X X X    X X 
Mosbech., 
2014, Denmark, 
Italy, Germany 
& France 
    X    X  X           1 y Oral lyophilisates containing D. 
pteronysinus and D. farinae in a 1:1 
ratio . Three active strengths 
were investigated: 1, 3, and 6 
SQ-HDM. 
  X    X X 
Mosges, 2007, 
Germany 
X         X X           9 
m 
Grass and rye pollen extract 
mixture  solution 
(Staloral(r) (Stallergenes, Antony, 
France)) and a tablet (freeze-
dried pollen extract) 
 X X    X  
Okubo, 2008, 
Japan 
 X       X  X   X X  X     7 
m 
Diluted cedar antigen extract (2 
to 2000 JAU/ml)  
 X     X X 
Ott, 2009, 
Germany 
X        X  X    X      X 3 y Pollen extract mixture of five 
grasses (cocksfoot or orchard, 
meadow, perennialrye, sweet 
vernal and timothy grasses; 
Staloral, Stallergenes SA,France) 
(300 IR/ml, equivalent to 21 
X X X X X X X  
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lg/ml of Phleum pratense major 
allergen)  
Nelson, 1993, 
US 
     X   X  X           10
5 d 
Cat dander extract (total dose: 
4.5 AU) 
X      X  
Pajno, 2003, 
Italy 
  X      X  X X X X X       14 
m 
P. judaica, fluticasone X X       
Palma-Carlos, 
2006, Italy 
X        X  X  X X        2 y Mixture of carbamylated grass 
pollens (Holcus lanatus 33%, 
Phleum pratense 33%, and Poa 
pratensis 33%) in tablets 
X      X  
Panzner, 2008, 
Czech Republic  
X        X  X   X        1 y Mixture of six grass pollen 
species extracts (oat grass 
(Arrhenatherum elatius), orchard 
grass (Dactylis glomerata), fescue 
(Festuca sp.), rye grass (Lolium sp.), 
timothy grass (Phleum pratense) 
and rye (Secale cereale)) (H-Al per 
os) (Sevapharma A.S., Prague, 
Czech Republic)  
 
X 
X     X  
Passalacqua, 
1996, Italy 
    X    X  X           2 y Monomeric allergoid tablets with 
Dermatophagoides pteronysinus and 
D farina 
X      X  
Passalacqua, 
1999, Italy 
X        X  X   X      X  7 
m 
ALK-Abello (major allergen Par 
j) (0.016, 0.08, 0.4, 2, and 10 
BU/mL)  
X X     X  
Passalacqua, 
2006, Italy 
    X    X  X     X      2 y Monomeric carbamylated grass 
pollen allergen (Lais) 
X X     X X 
Pfaar, 2008, 
Germany, 
Poland & 
Macedonia 
X        X  X           2 y Six-grass pollen mixture (high-
dose) 
X      X  
Pradalier, 1999, 
France 
X        X  X           4.5 
m 
Five-grass-pollen extracts 
(orchard grass, meadow grass, 
ryegrass, sweet vernal grass, and 
timothy grass) (Stallerge Ánes 
SA, Antony, France) 
X X     X  
Purello-
D'Ambrosio, 
1999, Italy 
  X      X  X   X      X  6 
m  
P. judaica extract (five 3-ml vials: 
0.016 BU/ml (vial 0), 0.08 (#1), 
0.04 (#2), 2.00 (#3), and 10.00 
(#4) in phyiologic saline with 
50% v/v of glycerol & 0.4% 
w/v of phenol) (maximum 
concentration of major allergen 
Par j 1: 0.6 mg/ml)  
X X     X  
Qeuiros, 2013, 
Brazil & US 
    X    X  X  X         18 
m 
SLIT 1:D. pteronysinus extract 
(FDA Allergenic Ltda, Rio de 
Janeiro, Brazil) SLIT 2: Dpt plus 
mixed respiratory bacterial 
(MRB) (FDA Allergenic Ltda) 
  X    X  
Rak, 2006, UK X        X  X           17
4 d 
Grass pollen allergen tablets 
(2,500, 25,000, and 75,000 SQ-
T)  
       X 
Roder, 2007, 
The 
Netherlands 
X        X  X     X      2 
yea
rs 
Aqueous extracts of 5 grass 
pollen (Lollium perenne, Phleum 
pratense, Dactylis glomeratein, 
Anthoxantum odoratum, Holcus 
lanatus) Oralgen grass pollen, 
Artu Biologicals 
X X     X X 
Rolinck-
Werninghaus, 
2004, Germany 
X        X  X     X
X 
     32 
m 
Pangramin (0.5 lg major 
allergens) (ALK-SCHERAX) 
three times weekly  
X X     X  
Sabbah, 1994, 
France 
X        X  X           4 
m 
Five-grass pollen extracts in 
glycerol-saline diluent (from 1 
drop of 1 IR/ml up to 20 drops 
of 100 IR/ml)  
X X     X  
Stelmach, 2011, 
Poland 
X        X  X   X X       2 y Staloral 300 IR with five grass 
pollen (Dactylis glomerata, 
Anthoxanthum odoratum, Lolium 
X X     X  
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perenne, Poa pratensis and Phleum 
pretense)  
Tari, 1990, Italy     X    X  X           18 
m 
Graded courses of aqueous mite 
extract with 0.4% phenol  
X      X  
Valovirta, 2006, 
Finland 
 X       X  X  X         19
m 
Intervention arm #1: Betula 
verrucosa, Corylus avellana and 
Alnus glutinosa (weekly dose: 24 
000 SQ-U); intervention arm #2: 
Betula verrucosa, Corylus avellana 
and Alnus glutinosa (weekly dose: 
200,000 SQ-U)  
X X     X  
Van Niekerk, 
1987, South 
Afri a 
X        X  X           24 
m 
Mixture of aqueous extracts of 
twelve grass pollens (B2 grasses) 
(Bencard, UK), plus Bermuda 
grass pollen and maize pollen in 
phosphate buffered phyiological 
saline  with 0 5% w/v phenol 
identical to Bencard SDV® 
vaccine (Beechams, UK)  
X      X  
Vourdas, 1998, 
Greece & 
France 
 X       X  X           2 y Olive pollen extract (major 
allergen Ole e 1  13.5 jig/ml (100 
IR/ml)) (four concentrations: 1, 
10, 100, and 300 IR/ml) 
(Stallergenes SA)  
X X     X  
Wang, 2013, 
China 
    X    X  X           6 
m 
Mixture of D. pteronysinus and D. 
farinae in 50% glycerol solution 
(Zhejiang Wolwo 
BioPharmaceutical Co., Ltd., 
China) (five treatment dosages 
with different concentrations: 
0.75 lg/ml, 7.5 lg/ml, 75 lg/ml, 
250 lg/ml, and 750 lg/ml)  
X X     X  
Wahn, 2012, 
Germany & 
Poland 
X        X  X   X X       8m Aqueous grass pollen 
preparation containing 6 species 
(Dactylis glomerata, Festuca pratensis, 
Holcus lanatus, Lolium perenne, 
Phleum pratense, and Poa pratensis) 
in a water/glycerol solution with 
phosphate-buffered saline (40 μg 
per maintenance dose) 
Allergopharma Joachim Ganzer 
KG, Reinbek, 
German  
  X    x  
Wahn, 2009, 
Denmark & 
France 
X        X  X   X X       Ap
pr
ox 
5-6 
m 
Aqueous mixture of 5 grass 
pollen extracts (orchard, 
meadow, perennial rye, sweet 
vernal, and timothy; Stallergenes 
SA, Antony, France) (300 IR)  
X X     X  
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Table 1c. Characteristics of ILIT studies (n = 2) 
 
Stu
dy 
(Fir
st 
aut
hor
, 
yea
r, 
cou
ntr
y) 
Allergen(s) type 
 
Alle
rge
n 
nu
mb
er 
Route 
AIT 
Compar
ator 
 
 
AIT Protocol 
Short term 
effectiveness 
L
o
n
g 
t
e
r
m
 
e
ff
e
c
ti
v
e
n
e
s
s 
SA
FE
TY
 
Q
u
al
it
y 
o
f 
lif
e
 
G
ra
ss
 p
o
lle
n
's
 
Tr
e
e
 p
o
lle
n
s 
W
e
e
d
s 
M
o
u
ld
s 
H
o
u
se
 d
u
st
 m
it
e
 
ca
t 
d
o
g 
o
th
e
r 
(s
) 
si
n
gl
e
 
M
u
lt
ip
le
 
SC
IT
 
SL
IT
 
IL
IT
 
p
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ce
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o
 
ro
u
ti
n
e
 c
ar
e
 
ac
ti
ve
 
    
 
P
re
-s
e
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o
n
al
 
C
o
-s
ea
so
n
al
 
C
o
n
ti
n
u
o
u
s 
C
o
n
ve
n
ti
o
n
al
 
C
lu
st
e
r 
Se
m
i-
ru
sh
 
R
u
sh
 
U
lt
ra
 r
u
sh
 
D
u
ra
ti
o
n
 o
f 
R
x 
Product type/ 
Name (manifacturer) 
Sy
m
p
to
m
 s
co
re
 
M
e
d
ic
at
io
n
 s
co
re
 
C
o
m
b
in
e
d
 s
co
re
 
Sy
m
p
to
m
 s
co
re
 
M
e
id
ic
at
io
n
 s
co
re
 
C
o
m
b
in
e
d
  s
co
re
  
Hyl
an
der 
et 
al,  
20
16,  
Spa
in 
X X       X    X X   X    X    2
 
m
o
s 
aluminium hydroxide 
adsorbed, depot 
birch- or grass-pollen 
vaccine / Alutard (ALK 
Abéllo) 
X X     X  
Sen
ti, 
et 
al ,  
201
2, 
Swi
tzer
lan
d 
     X   X    X X     X  X    2
 
m
o
s 
recombinant major 
cat dander allergen 
Fel d 1 fused to a 
modular antigen 
transporter (MAT) 
vaccine (MAT–Fel d 
1)/ NR (extract 
purchased from 
Stallergenes) 
X
* 
   
  
X X 
 
* assessment after 300 days of discontinuation of ILIT 
AIT, allergen specific  immunotherapy; mo, month; NR, not reported;  Rx, treatment; SCIT, subcutaneous immunotherapy; 
SLIT, sublingual immunotherapy, ; ILIT, intralymphatic immunotherapy.  
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Figure 1: PRISMA Diagram 
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Figure 2: Meta-analysis of double-blind RCTs comparing symptom scores between AIT (SCIT 
or SLIT) and placebo groups (random-effects model) 
 
 
 
 
Heterogeneity: τ2 = 0.090; χ2 = 173.586, df = 57 (P<0.0001); I2 = 67%; 
Test for overall effect: Z = -9.992 (P<0.0001) 
*denotes SCIT studies 
Study name Statistics for each study Sample size Std diff in means and 95%  CI
Std diff Lower Upper Relative 
in means limit limit Treatment Control weight
Amar 2009 0.030 -0.625 0.684 19 17 1.39
Andre 2003 -0.449 -0.848 -0.050 48 51 2.13
Ariano 2001 -2.274 -3.398 -1.149 10 10 0.67
Bahceciler 2001 0.333 -0.689 1.354 8 7 0.77
Bowen 2004 -0.433 -0.888 0.022 37 39 1.94
Bufe 2004 -0.058 -0.399 0.284 68 64 2.32
Bufe 2009 -0.221 -0.476 0.034 117 121 2.62
Caffarelli 2000 -0.453 -1.134 0.228 17 17 1.33
Cortellini 2010 -1.457 -2.310 -0.604 15 12 1.00
Creticos 2014 -0.297 -0.487 -0.107 218 211 2.81
Dahl 2006a -0.637 -1.074 -0.199 61 32 2.00
Dahl 2006b -0.519 -0.687 -0.352 282 286 2.88
de Blay 2003 -0.167 -0.624 0.289 33 42 1.94
de Bot 2011 0.069 -0.192 0.330 110 116 2.60
Didier 2007 -0.434 -0.670 -0.198 136 148 2.68
Drachenbergh 2001 -0.268 -0.921 0.386 37 12 1.39
Durham 2006 -0.229 -0.473 0.015 131 129 2.65
Feliziani 1995 -1.028 -1.744 -0.312 18 16 1.25
Guez 2000 -0.416 -0.883 0.051 36 36 1.90
Halken 2010 -0.437 -0.680 -0.193 131 135 2.65
Hirsch 1997 0.525 -0.329 1.378 12 10 1.00
Horak 2009 -0.778 -1.208 -0.347 45 44 2.02
Hordijk 1998 -0.575 -1.050 -0.100 35 36 1.88
La Rosa 1999 -0.249 -0.934 0.437 16 17 1.32
Marcucci 2003 -0.235 -1.041 0.571 13 11 1.08
Nelson 1993 -0.570 -1.194 0.055 20 21 1.46
Ott 2009 -0.515 -0.829 -0.202 123 60 2.42
Paino 2003 -0.850 -1.638 -0.061 14 13 1.11
Palma Carlos 2006 -0.585 -1.283 0.112 17 16 1.29
Panzner 2008 -1.291 -2.025 -0.556 20 15 1.21
Passalacqua 1998 -1.327 -2.321 -0.332 10 9 0.80
Passalacqua 1999 -0.018 -0.734 0.698 15 15 1.25
Passalacqua 2006 -1.624 -2.228 -1.020 28 28 1.51
Pfaar 2008 -0.699 -1.125 -0.272 42 48 2.03
Pradalier 1999 -0.177 -0.527 0.173 63 63 2.29
Rolinck-Werninghaus 2004 0.047 -0.400 0.494 39 38 1.97
Stelmach 2012 -1.165 -1.862 -0.468 19 18 1.29
Tari 1990 -2.274 -2.935 -1.613 30 28 1.37
Valovirta 2006 -0.500 -1.032 0.032 27 29 1.71
Vourdas 1998 -0.170 -0.654 0.314 34 32 1.85
Wahn 2009 -0.435 -0.678 -0.192 131 135 2.65
Balda 1998* -0.270 -0.655 0.115 49 56 2.17
Bodtger 2002* -0.900 -1.616 -0.183 16 17 1.25
Bousquet 1990* -1.371 -2.078 -0.663 20 18 1.27
Charpin 2007* -0.694 -1.409 0.021 17 15 1.25
Corrigan 2005* -0.410 -0.729 -0.091 77 77 2.40
Drachenberg 2001* -0.467 -0.831 -0.104 74 50 2.25
Ferrer 2005* -0.821 -1.451 -0.191 22 20 1.44
Frew 2006* -0.493 -0.749 -0.238 187 89 2.61
Jutel 2005* -0.563 -1.092 -0.033 29 28 1.71
Klimek 2014* -0.599 -0.963 -0.234 61 60 2.24
Ortolani 1994* -2.457 -3.335 -1.579 18 17 0.96
Tabar 2008* 0.313 -0.432 1.058 14 14 1.19
Varney 1991* -0.466 -1.140 0.208 19 16 1.34
Varney 2003* -1.588 -2.439 -0.737 15 13 1.00
Walker 2001* -0.515 -1.249 0.219 17 13 1.21
Weyer 1981* -0.554 -1.250 0.141 17 16 1.29
Zenner 1997* -0.453 -0.894 -0.012 41 40 1.99
-0.527 -0.631 -0.424 2978 2746
-4.00 -2.00 0.00 2.00 4.00
Favours active Favours placebo
Heterogeneity: Tau2 = 0.46; Chi2 = 48.94, df = 17 (P<0.0001); I2 = 65%; Test for overall effect: Z = -5.75 (P<0.0001)
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Figure 3: Meta-analysis of double-blind RCTs comparing symptom scores between (a) SCIT and 
placebo groups and (b) SLIT and placebo group (random-effects models) 
a) 
 
Heterogeneity: τ2 = 0.106; χ2 = 39.357, df = 15 (P<0.001); I2 = 62%; 
Test for overall effect: Z = -5.875 (P<0.0001) 
*denotes SCIT studies 
 
Study name Statistics for each study Sample size Std diff in means and 95% CI
Std diff Lower Upper Relative 
in means limit limit Treatment Control weight
Balda 1998* -0.270 -0.655 0.115 49 56 8.37
Bodtger 2002* -0.900 -1.616 -0.183 16 17 5.06
Bousquet 1990* -1.371 -2.078 -0.663 20 18 5.13
Charpin 2007* -0.694 -1.409 0.021 17 15 5.07
Corrigan 2005* -0.410 -0.729 -0.091 77 77 9.14
Drachenberg 2001* -0.467 -0.831 -0.104 74 50 8.63
Ferrer 2005* -0.821 -1.451 -0.191 22 20 5.79
Frew 2006* -0.493 -0.749 -0.238 187 89 9.84
Jutel 2005* -0.563 -1.092 -0.033 29 28 6.77
Ortolani 1994* -2.457 -3.335 -1.579 18 17 3.96
Tabar 2008* 0.313 -0.432 1.058 14 14 4.84
Varney 1991* -0.466 -1.140 0.208 19 16 5.41
Varney 2003* -1.588 -2.439 -0.737 15 13 4.12
Walker 2001* -0.515 -1.249 0.219 17 13 4.93
Weyer 1981* -0.554 -1.250 0.141 17 16 5.23
Zenner 1997* -0.453 -0.894 -0.012 41 40 7.73
-0.648 -0.864 -0.432 632 499
-4.00 -2.00 0.00 2.00 4.00
Favours active Favours placebo
Heterogeneity: Tau2 = 2.108; Chi2 = 266.517, df = 4; (P<0.0001); I2 = 98%; Test for overall effect: Z = -1.772 (P<0.076)
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b)
 
Heterogeneity: τ2 = 0.088; χ2 = 129.171, df = 40 (P<0.0001); I2 = 69%; 
Test for overall effect: Z = -7.855 (P<0.0001) 
*denotes SCIT studies 
  
Study name Statistics for each study Sample size Std diff in means and 95% CI
Std diff Lower Upper Relative 
in means limit limit Treatment Control weight
Amar 2009 0.030 -0.625 0.684 19 17 1.91
Andre 2003 -0.449 -0.848 -0.050 48 51 2.94
Ariano 2001 -2.274 -3.398 -1.149 10 10 0.91
Bahceciler 2001 0.333 -0.689 1.354 8 7 1.06
Bowen 2004 -0.433 -0.888 0.022 37 39 2.68
Bufe 2004 -0.058 -0.399 0.284 68 64 3.21
Bufe 2009 -0.221 -0.476 0.034 117 121 3.62
Caffarelli 2000 -0.453 -1.134 0.228 17 17 1.82
Cortellini 2010 -1.457 -2.310 -0.604 15 12 1.37
Creticos 2014 -0.297 -0.487 -0.107 218 211 3.90
Dahl 2006a -0.637 -1.074 -0.199 61 32 2.76
Dahl 2006b -0.519 -0.687 -0.352 282 286 3.99
de Blay 2003 -0.167 -0.624 0.289 33 42 2.67
de Bot 2011 0.069 -0.192 0.330 110 116 3.60
Didier 2007 -0.434 -0.670 -0.198 136 148 3.71
Drachenbergh 2001 -0.268 -0.921 0.386 37 12 1.91
Durham 2006 -0.229 -0.473 0.015 131 129 3.67
Feliziani 1995 -1.028 -1.744 -0.312 18 16 1.72
Guez 2000 -0.416 -0.883 0.051 36 36 2.63
Halken 2010 -0.437 -0.680 -0.193 131 135 3.68
Hirsch 1997 0.525 -0.329 1.378 12 10 1.37
Horak 2009 -0.778 -1.208 -0.347 45 44 2.79
Hordijk 1998 -0.575 -1.050 -0.100 35 36 2.59
La Rosa 1999 -0.249 -0.934 0.437 16 17 1.81
Marcucci 2003 -0.235 -1.041 0.571 13 11 1.48
Nelson 1993 -0.570 -1.194 0.055 20 21 2.01
Ott 2009 -0.515 -0.829 -0.202 123 60 3.35
Paino 2003 -0.850 -1.638 -0.061 14 13 1.53
Palma Carlos 2006 -0.585 -1.283 0.112 17 16 1.78
Panzner 2008 -1.291 -2.025 -0.556 20 15 1.67
Passalacqua 1998 -1.327 -2.321 -0.332 10 9 1.10
Passalacqua 1999 -0.018 -0.734 0.698 15 15 1.72
Passalacqua 2006 -1.624 -2.228 -1.020 28 28 2.08
Pfaar 2008 -0.699 -1.125 -0.272 42 48 2.81
Pradalier 1999 -0.177 -0.527 0.173 63 63 3.17
Rolinck-Werninghaus 2004 0.047 -0.400 0.494 39 38 2.72
Stelmach 2012 -1.165 -1.862 -0.468 19 18 1.78
Tari 1990 -2.274 -2.935 -1.613 30 28 1.89
Valovirta 2006 -0.500 -1.032 0.032 27 29 2.35
Vourdas 1998 -0.170 -0.654 0.314 34 32 2.56
Wahn 2009 -0.435 -0.678 -0.192 131 135 3.68
-0.485 -0.606 -0.364 2285 2187
-4.00 -2.00 0.00 2.00 4.00
Favours active Favours placebo
Heterogeneity: Tau2 = 2.108; Chi2 = 266.517, df = 4; (P<0.0001); I2 = 98%; Test for overall effect: Z = -1.772 (P<0.076)
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Figure 4: Meta-analysis of double-blind RCTs comparing symptom scores between AIT (SCIT 
or SLIT) and placebo group in (a) those <18 years old and (b) those≥18 years old (random-
effects models) 
a) 
 
 
Heterogeneity: τ2 = 0.059; χ2 = 24.209, df = 11 (P<0.012); I2 = 54%; 
Test for overall effect: Z = -2.423 (P<0.015) 
 
 
 
 
 
 
 
 
 
 
 
 
Study name Statistics for each study Sample size Std diff in means and 95% CI
Std diff Lower Upper Relative 
in means limit limit Treatment Control weight
Bahceciler 2001 0.333 -0.689 1.354 8 7 3.32
Bufe 2009 -0.221 -0.476 0.034 117 121 14.38
Caffarelli 2000 -0.453 -1.134 0.228 17 17 6.10
de Bot 2011 0.069 -0.192 0.330 110 116 14.23
Halken 2010 -0.437 -0.680 -0.193 131 135 14.67
Hirsch 1997 0.525 -0.329 1.378 12 10 4.41
Marcucci 2003 -0.235 -1.041 0.571 13 11 4.81
Paino 2003 -0.850 -1.638 -0.061 14 13 4.97
Rolinck-Werninghaus 2004 0.047 -0.400 0.494 39 38 9.85
Stelmach 2012 -1.165 -1.862 -0.468 19 18 5.90
Valovirta 2006 -0.500 -1.032 0.032 27 29 8.24
Vourdas 1998 -0.170 -0.654 0.314 34 32 9.13
-0.254 -0.459 -0.048 541 547
-4.00 -2.00 0.00 2.00 4.00
Favours active Favours placebo
Heterogeneity: Tau2 = 2.108; Chi2 = 266.517, df = 4; (P<0.0001); I2 = 98%; Test for overall effect: Z = -1.772 (P<0.076)
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b) 
 
Heterogeneity: τ2 = 0.057; χ2 = 57.748 df = 22 (P<0.0001); I2 = 62%; 
Test for overall effect: Z = -7.969 (P<0.0001) 
*denotes SCIT studies 
 
 
 
 
 
 
 
 
 
 
 
Study name Statistics for each study Sample size Std diff in means and 95% CI
Std diff Lower Upper Relative 
in means limit limit Treatment Control weight
Amar 2009 0.030 -0.625 0.684 19 17 2.93
Creticos 2014 -0.297 -0.487 -0.107 218 211 7.45
Dahl 2006a -0.637 -1.074 -0.199 61 32 4.62
Dahl 2006b -0.519 -0.687 -0.352 282 286 7.70
Didier 2007 -0.434 -0.670 -0.198 136 148 6.93
Durham 2006 -0.229 -0.473 0.015 131 129 6.82
Horak 2009 -0.778 -1.208 -0.347 45 44 4.69
Hordijk 1998 -0.575 -1.050 -0.100 35 36 4.27
Nelson 1993 -0.570 -1.194 0.055 20 21 3.11
Palma Carlos 2006 -0.585 -1.283 0.112 17 16 2.68
Passalacqua 1999 -0.018 -0.734 0.698 15 15 2.59
Passalacqua 2006 -1.624 -2.228 -1.020 28 28 3.24
Balda 1998* -0.270 -0.655 0.115 49 56 5.17
Bodtger 2002* -0.900 -1.616 -0.183 16 17 2.59
Charpin 2007* -0.694 -1.409 0.021 17 15 2.59
Corrigan 2005* -0.410 -0.729 -0.091 77 77 5.92
Drachenberg 2001* -0.467 -0.831 -0.104 74 50 5.41
Frew 2006* -0.493 -0.749 -0.238 187 89 6.68
Klimek 2014* -0.599 -0.963 -0.234 61 60 5.40
Ortolani 1994* -2.457 -3.335 -1.579 18 17 1.91
Varney 1991* -0.466 -1.140 0.208 19 16 2.81
Varney 2003* -1.588 -2.439 -0.737 15 13 2.00
Walker 2001* -0.515 -1.249 0.219 17 13 2.50
-0.559 -0.696 -0.421 1557 1406
-4.00 -2.00 0.00 2.00 4.00
Favours active Favours placebo
Heterogeneity: Tau2 = 2.108; Chi2 = 266.517, df = 4; (P<0.0001); I2 = 98%; Test for overall effect: Z = -1.772 (P<0.076)
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Figure 5: Meta-analysis of double-blind RCTs studies comparing medication scores between 
AIT (SCIT or SLIT) and placebo groups (random-effects model) 
 
 
 
Heterogeneity: τ2 = 0.074; χ2 = 110.337, df = 44 (P<0.0001); I2 = 60%; 
Test for overall effect: Z = -6.502 (P<0.0001) 
*denotes SCIT studies 
 
 
 
 
Study name Statistics for each study Sample size Std diff in means and 95%  CI
Std diff Lower Upper Relative 
in means limit limit Treatment Control weight
Amar 2009 0.338 -0.321 0.997 19 17 1.77
Andre 2003 -0.502 -0.902 -0.101 48 51 2.86
Ariano 2001 -0.743 -1.649 0.163 10 10 1.15
Bahceciler 2001 -0.280 -1.300 0.739 8 7 0.96
Bowen 2004 -0.147 -0.598 0.303 37 39 2.61
Bufe 2004 0.316 -0.028 0.659 68 64 3.16
Bufe 2009 -0.123 -0.377 0.132 117 121 3.64
Caffarelli 2000 -0.135 -0.808 0.538 17 17 1.73
Dahl 2006a -0.453 -0.886 -0.021 61 32 2.69
Dahl 2006b -0.405 -0.571 -0.239 282 286 4.07
de Blay 2003 -0.575 -1.040 -0.109 33 42 2.54
Drachenberg 2001 -0.544 -1.204 0.116 37 12 1.77
Durham 2006 -0.278 -0.523 -0.034 131 129 3.69
Feliziani 1995 -1.322 -2.065 -0.579 18 16 1.52
Guez 2000 -0.323 -0.788 0.142 36 36 2.54
Hordijk 1998 -0.364 -0.833 0.105 35 36 2.52
La Rosa 1999 -0.020 -0.703 0.662 16 17 1.70
Marcucci 2003 -0.749 -1.579 0.081 13 11 1.31
Ott 2009 0.067 -0.242 0.375 123 60 3.34
Pajno 2003 -1.273 -2.100 -0.445 14 13 1.31
Palma Carlos 2006 -0.571 -1.268 0.125 17 16 1.65
Passalacqua 1999 -0.710 -1.448 0.028 15 15 1.54
Passalacqua 2006 -1.409 -1.994 -0.823 28 28 2.03
Pradalier 1999 -0.144 -0.493 0.206 63 63 3.12
Rolinck-Werninghaus 2004 -0.083 -0.530 0.364 39 38 2.63
Stelmach 2012 0.242 -0.405 0.889 19 18 1.81
Valovirta 2006 -0.246 -0.772 0.280 27 29 2.27
Vourdas 1998 -0.105 -0.588 0.378 34 32 2.46
Wahn 2009 -0.302 -0.544 -0.060 131 135 3.70
Balda 1998* -0.255 -0.640 0.130 49 56 2.94
Bodtger 2002* -0.591 -1.278 0.096 17 17 1.68
Bousquet 1990* -0.620 -1.272 0.032 20 18 1.79
Charpin 2007* -0.293 -0.991 0.405 17 15 1.65
Corrigan 2005* -0.291 -0.609 0.026 77 77 3.30
Dolz 1996* -3.663 -4.895 -2.431 18 10 0.71
Drachenber 2001* -0.231 -0.591 0.129 74 50 3.07
Ferrer 2005* -0.460 -1.073 0.154 22 20 1.93
Frew 2006* -0.432 -0.687 -0.177 187 89 3.63
Jutel 2005* -0.223 -0.744 0.298 29 28 2.29
Mirone 2004* -0.614 -1.451 0.223 11 12 1.29
Tabar 2008* 0.341 -0.405 1.087 14 14 1.51
Varney 1991* -1.196 -1.917 -0.474 19 16 1.58
Varney 2003* -0.267 -1.013 0.479 15 13 1.51
Walker 2001* -0.963 -1.736 -0.191 16 13 1.44
Weyer 1981* -0.822 -1.533 -0.111 17 16 1.61
-0.375 -0.487 -0.262 2098 1854
-4.00 -2.00 0.00 2.00 4.00
Favours active Favours placebo
Heterogeneity: Tau2 = 0.46; Chi2 = 48.94, df = 17 (P<0.0001); I2 = 65%; Test for overall effect: Z = -5.75 (P<0.0001)
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Figure 6: Meta-analysis of double-blind RCTs comparing medication scores between (a) SCIT 
and placebo groups and (b) SLIT and placebo groups (random-effects models) 
a) 
 
Heterogeneity: τ2 = 0.126; χ2 = 42.241, df = 15 (P<0.0001); I2 = 64%; 
Test for overall effect: Z = -4.399 (P<0.0001) 
*denotes SCIT studies 
 
 
 
 
 
 
 
 
 
 
 
Study name Statistics for each study Sample size Std diff in means and 95% CI
Std diff Lower Upper Relative 
in means limit limit Treatment Control weight
Balda 1998* -0.255 -0.640 0.130 49 56 8.50
Bodtger 2002* -0.591 -1.278 0.096 17 17 5.63
Bousquet 1990* -0.620 -1.272 0.032 20 18 5.92
Charpin 2007* -0.293 -0.991 0.405 17 15 5.54
Corrigan 2005* -0.291 -0.609 0.026 77 77 9.19
Dolz 1996* -3.663 -4.895 -2.431 18 10 2.69
Drachenber 2001* -0.231 -0.591 0.129 74 50 8.76
Ferrer 2005* -0.460 -1.073 0.154 22 20 6.25
Frew 2006* -0.432 -0.687 -0.177 187 89 9.79
Jutel 2005* -0.223 -0.744 0.298 29 28 7.12
Mirone 2004* -0.614 -1.451 0.223 11 12 4.54
Tabar 2008* 0.341 -0.405 1.087 14 14 5.17
Varney 1991* -1.196 -1.917 -0.474 19 16 5.35
Varney 2003* -0.267 -1.013 0.479 15 13 5.17
Walker 2001* -0.963 -1.736 -0.191 16 13 4.97
Weyer 1981* -0.822 -1.533 -0.111 17 16 5.43
-0.521 -0.753 -0.289 602 464
-4.00 -2.00 0.00 2.00 4.00
Favours active Favours placebo
Heterogeneity: Tau2 = 2.108; Chi2 = 266.517, df = 4; (P<0.0001); I2 = 98%; Test for overall effect: Z = -1.772 (P<0.076)
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b) 
 
Heterogeneity: τ2 = 0.057; χ2 = 64.535, df = 28 (P<0.0001); I2 = 57%; 
Test for overall effect: Z = -4.805 (P<0.0001) 
 
 
 
 
 
 
 
 
 
 
 
Study name Statistics for each study Sample size Std diff in means and 95% CI
Std diff Lower Upper Relative 
in means limit limit Treatment Control weight
Amar 2009 0.338 -0.321 0.997 19 17 2.46
Andre 2003 -0.502 -0.902 -0.101 48 51 4.24
Ariano 2001 -0.743 -1.649 0.163 10 10 1.55
Bahceciler 2001 -0.280 -1.300 0.739 8 7 1.28
Bowen 2004 -0.147 -0.598 0.303 37 39 3.81
Bufe 2004 0.316 -0.028 0.659 68 64 4.77
Bufe 2009 -0.123 -0.377 0.132 117 121 5.67
Caffarelli 2000 -0.135 -0.808 0.538 17 17 2.40
Dahl 2006a -0.453 -0.886 -0.021 61 32 3.96
Dahl 2006b -0.405 -0.571 -0.239 282 286 6.52
de Blay 2003 -0.575 -1.040 -0.109 33 42 3.70
Drachenberg 2001 -0.544 -1.204 0.116 37 12 2.46
Durham 2006 -0.278 -0.523 -0.034 131 129 5.77
Feliziani 1995 -1.322 -2.065 -0.579 18 16 2.09
Guez 2000 -0.323 -0.788 0.142 36 36 3.70
Hordijk 1998 -0.364 -0.833 0.105 35 36 3.67
La Rosa 1999 -0.020 -0.703 0.662 16 17 2.35
Marcucci 2003 -0.749 -1.579 0.081 13 11 1.77
Ott 2009 0.067 -0.242 0.375 123 60 5.12
Pajno 2003 -1.273 -2.100 -0.445 14 13 1.78
Palma Carlos 2006 -0.571 -1.268 0.125 17 16 2.29
Passalacqua 1999 -0.710 -1.448 0.028 15 15 2.11
Passalacqua 2006 -1.409 -1.994 -0.823 28 28 2.87
Pradalier 1999 -0.144 -0.493 0.206 63 63 4.71
Rolinck-Werninghaus 2004 -0.083 -0.530 0.364 39 38 3.84
Stelmach 2012 0.242 -0.405 0.889 19 18 2.52
Valovirta 2006 -0.246 -0.772 0.280 27 29 3.25
Vourdas 1998 -0.105 -0.588 0.378 34 32 3.56
Wahn 2009 -0.302 -0.544 -0.060 131 135 5.80
-0.311 -0.438 -0.184 1496 1390
-4.00 -2.00 0.00 2.00 4.00
Favours active Favours placebo
Heterogeneity: Tau2 = 2.108; Chi2 = 266.517, df = 4; (P<0.0001); I2 = 98%; Test for overall effect: Z = -1.772 (P<0.076)
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Figure 7: Meta-analysis of double-blind RCTs studies comparing combined symptom and 
medication scores between AIT (SCIT or SLIT) and placebo groups (random-effects model) 
 
 
Heterogeneity: τ2 = 0.071; χ2 = 33.631, df = 14 (P<0.002); I2 = 58%; 
Test for overall effect: Z = -4.997 (P<0.001) 
*denotes SCIT studies 
 
 
 
 
 
 
 
 
 
 
  
Study name Statistics for each study Sample size Std diff in means and 95%  CI
Std diff Lower Upper Relative 
in means limit limit Treatment Control weight
Cortellini 2010 -1.284 -2.117 -0.451 15 12 3.86
Creticos 2014 -0.303 -0.493 -0.112 218 211 12.06
Ott 2009 -0.157 -0.466 0.152 123 60 10.12
Stelmach 2012 -0.846 -1.519 -0.173 19 18 5.14
Balda 1998* -0.215 -0.600 0.169 49 56 8.86
Corrigan 2005* -0.449 -0.769 -0.129 77 77 9.94
Drachenberg 2001* -0.378 -0.740 -0.016 74 50 9.23
Ferrer 2005* -0.857 -1.489 -0.224 22 20 5.54
Horst 1990* -1.421 -2.319 -0.523 13 11 3.46
Jutel 2005* -0.441 -0.967 0.084 29 28 6.79
Ortolani 1994* -1.149 -1.865 -0.434 18 17 4.76
Pastorello 1992* -1.278 -2.266 -0.290 10 9 2.99
Tabar 2008* 0.723 -0.042 1.487 14 14 4.35
Weyer 1981* -0.691 -1.393 0.012 17 16 4.87
Zenner 1997* -0.337 -0.776 0.102 41 40 8.02
-0.493 -0.686 -0.299 739 639
-4.00 -2.00 0.00 2.00 4.00
Favours active Favours placebo
Heterogeneity: Tau2 = 0.46; Chi2 = 48.94, df = 17 (P<0.0001); I2 = 65%; Test for overall effect: Z = -5.75 (P<0.0001)
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Figure 8: Meta-analysis of double-blind RCTs comparing combined symptom and medication 
scores between (a) SCIT and placebo groups and (b) SLIT and placebo groups (random-effects 
models) 
a) 
 
Heterogeneity: τ2 = 0.096; χ2 = 23.777, df = 10 (P<0.008); I2 = 58%; 
Test for overall effect: Z = -3.984 (P<0.0001) 
*denotes SCIT studies 
 
b) 
 
 
 
Heterogeneity: τ2 = 0.070; χ2 = 8.584, df = 3 (P<0.035); I2 = 65%; 
Test for overall effect: Z = -2.648 (P<0.008) 
 
 
 
Study name Statistics for each study Sample size Std diff in means and 95% CI
Std diff Lower Upper Relative 
in means limit limit Treatment Control weight
Balda 1998* -0.215 -0.600 0.169 49 56 12.39
Corrigan 2005* -0.449 -0.769 -0.129 77 77 13.59
Drachenberg 2001* -0.378 -0.740 -0.016 74 50 12.81
Ferrer 2005* -0.857 -1.489 -0.224 22 20 8.32
Horst 1990* -1.421 -2.319 -0.523 13 11 5.44
Jutel 2005* -0.441 -0.967 0.084 29 28 9.92
Ortolani 1994* -1.149 -1.865 -0.434 18 17 7.26
Pastorello 1992* -1.278 -2.266 -0.290 10 9 4.75
Tabar 2008* 0.723 -0.042 1.487 14 14 6.71
Weyer 1981* -0.691 -1.393 0.012 17 16 7.41
Zenner 1997* -0.337 -0.776 0.102 41 40 11.40
-0.514 -0.766 -0.261 364 338
-4.00 -2.00 0.00 2.00 4.00
Favours active Favours placebo
Heterogeneity: Tau2 = 2.108; Chi2 = 266.517, df = 4; (P<0.0001); I2 = 98%; Test for overall effect: Z = -1.772 (P<0.076)
Study name Statistics for each study Sample size Std diff in means and 95% CI
Std diff Lower Upper Relative 
in means limit limit Treatment Control weight
Cortellini 2010 -1.284 -2.117 -0.451 15 12 12.33
Creticos 2014 -0.303 -0.493 -0.112 218 211 38.76
Ott 2009 -0.157 -0.466 0.152 123 60 32.48
Stelmach 2012 -0.846 -1.519 -0.173 19 18 16.43
-0.466 -0.810 -0.121 375 301
-4.00 -2.00 0.00 2.00 4.00
Favours active Favours placebo
Heterogeneity: Tau2 = 2.108; Chi2 = 266.517, df = 4; (P<0.0001); I2 = 98%; Test for overall effect: Z = -1.772 (P<0.076)
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Figure 9: Meta-analysis of double-blind RCTs comparing quality of life scores between SCIT 
and placebo groups (random-effects models) 
 
 
 
 
 
Heterogeneity: τ2 = 0.186; χ2 = 28.432, df = 5 (P<0.0001); I2 = 82%; 
Test for overall effect: Z = -1.764 (P<0.078) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study name Statistics for each study Sample size Std diff in means and 95% CI
Std diff Lower Upper Relative 
in means limit limit Treatment Control weight
Corrigan 2005 -0.270 -0.588 0.047 77 77 18.72
Ferrer 2005 -0.606 -1.232 0.020 21 20 13.80
Frew 2006 -0.639 -0.895 -0.382 183 92 19.56
Jutel 2005 -0.595 -1.126 -0.064 29 28 15.33
Riechelmann 2010 0.443 0.107 0.778 66 74 18.45
Walker 2001 -0.589 -1.193 0.015 22 22 14.15
-0.352 -0.743 0.039 398 313
-4.00 -2.00 0.00 2.00 4.00
Favours active Favours placebo
Heterogeneity: Tau2 = 2.108; Chi2 = 266.517, df = 4; (P<0.0001); I2 = 98%; Test for overall effect: Z = -1.772 (P<0.076)
